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Abstract 
 
Alzheimer’s disease (AD) is the most common form of progressive neurodegenerative 
disorders afflicting more than 47 million people worldwide. This poses a significant economic 
cost and highlights the need to develop disease-modifying therapeutic strategies. AD is 
characterised by the formation of extracellular amyloid beta (Aβ) plaques and intracellular 
neurofibrillary tangles. It has been shown that the 37kDa/67kDa laminin receptor (LRP/LR) 
and telomerase are implicated in the pathogenesis of AD through their respective interactions 
with Aβ and the AD-associated proteins: the amyloid precursor protein (APP), β- and γ-
secretase. Aβ inhibits telomerase activity and LRP/LR has a function in regulating telomerase 
activity as well as in the internalisation and shedding of Aβ.  We have previously shown in 
vitro, that blockade of the 37kDa/67kDa Laminin Receptor (LRP/LR) with the anti-LRP/LR 
specific antibody, IgG1-iS18, resulted in reduced Aβ-induced cytotoxicity and Aβ 
accumulation. The current study consisted of two parts, in vivo analysis to determine the effect 
of blocking LRP/LR with IgG1-iS18 and in vitro analysis on the overexpression of LRP 
intracellularly. To test the effect of blocking LRP/LR on Aβ formation and AD associated 
symptoms, 5XFAD AD transgenic mice received IgG1-iS18 through intranasal administration. 
The 5XFAD mice harbour three mutant human APP (695) and two PS1 Familial AD mutations 
to induce amyloid pathology through overexpression of APP. Furthermore, the resultant effects 
on the expression of the AD-related proteins, mTERT and γH2AX expression were 
investigated. We show that this treatment resulted in an improvement in memory, decreased 
vacuolization and Aβ plaque formation. Moreover, a significant decrease in Aβ42 protein 
expression with a concomitant increase in APP and telomerase reverse transcriptase (mTERT) 
levels was observed. These data indicate IgG1-iS18 as a potentially powerful therapeutic tool 
for AD. To investigate the effect of overexpressing LRP in in vitro AD models, the SH-SY5Y 
neuronal and HEK293 AD cell culture models were stably transfected with pCIneo-
moLRP::FLAG, to induce overexpression of LRP. This treatment resulted in increased LRP 
and hTERT levels, with co-localisation between the LRP and hTERT, together with a 
concomitant decrease in Aβ levels. Additionally, this treatment increased telomerase activity 
and rescued cells from Aβ-mediated cytotoxicity. These data suggest that overexpression of 
LRP intracellularly might represent a potential therapeutic strategy for treatment of AD. Taken 
altogether, targeting LRP/LR in an AD context has provided insight into the disease and 
simultaneously provided alternative therapeutic options for halting AD progression. 
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1. Introduction 
1.1. Alzheimer’s disease epidemiology 
Alzheimer’s disease (AD) is the most common form of progressive neurodegenerative 
disorders afflicting in excess of 47 million people on a worldwide basis, of which there are 
approximately 186, 000 people living with Dementia in South Africa. These numbers are 
expected to double by 2030 and more than triple by 2050 (Alzheimer’s Disease International, 
2015). Dementia causes overwhelming effects on those suffering from it, as well as their 
caregivers, families, and societies physically, psychologically and economically. 
Unfortunately, lack of awareness and understanding of Dementia in most countries results in 
stigmatization as well as barriers to both diagnosis and care.  This most prevalent form of 
Dementia predominantly affects the ageing population and is of significant economic cost, 
whereby in 2015, the global cost was estimated at 818 billion USD (Alzheimer’s Disease 
International, 2015). In 2015, 9.9 million new cases of Dementia were reported (Alzheimer’s 
Disease International, 2015), which equates to one every three seconds. The World Health 
Organization has ranked South Africa 31st in the world in terms of death rate for 
AD/Dementia and this statistic is based on underrepresented data, attributable to a lack of 
epidemiological data to provide representative estimates. Additionally, due to the knowledge 
gap which currently exists in the understanding of the disease-causing mechanism and that 
presently, only palliative therapeutic options are available, research based on the 
development of therapeutic strategies for AD is of high priority. 
It is of great concern that South Africa’s public healthcare system is principally focussed on 
addressing primary healthcare needs such as HIV/AIDS and tuberculosis. In reality, more 
than 19.4 million people in eastern and southern Africa are living with HIV/AIDS, with an 
estimated 790 000 people dying from the devastating disease in these regions, in 2016 
(UNAIDS Fact Sheet, 2017). Many of the deceased are young parents, and this leaves the 
burden of childcare on the aged and so often the elderly grandparents suffering with 
Dementia are left without children to care for them. The reality is that government spending 
will continue to address the high demands associated with primary healthcare needs. Whilst 
there is an understanding of this need, this only highlights the alarming statistics which 
provide proof of the necessity for disease-modifying treatment strategies for 
neurodegenerative disorders such as AD. Ultimately, there is a great need for readily 
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available and inexpensive treatments which impede the progression of AD, thus reducing the 
need for care and thus reducing costs on all fronts. 
1.2. Alzheimer’s disease pathology and molecular mechanisms 
AD is characterised by two key neuropathological hallmarks: (i) the accumulation of the 
neurotoxic amyloid beta-42 (Aβ42) peptide, resulting in the development of extracellular 
amyloid beta plaques (Xiao et al., 2015), thereby causing neuronal loss (Serrano-Pozo et al., 
2011) and (ii) the aggregation of hyper-phosphorylated tau (a microtubule associated 
protein), producing intracellular neurofibrillary tangles, leading to synaptic loss (Avila, 
2006). Collectively, it is these factors and their associations, which cause the progressive and 
devastating behavioural and cognitive dysfunction symptoms as seen in those suffering from 
AD. 
The 4-kDa Aβ peptide is the candidate etiological cause for AD, expressly, it is the 42 amino 
acid (aa) Aβ peptide which amasses to cause the neurotoxic effects present in AD (Choi et 
al., 2014). Generation of the Aβ peptide occurs via the amyloidogenic pathway, when the 
amyloid precursor protein (APP) in the cell membrane, is sequentially cleaved by β-secretase 
(also known as BACE1 – B-site APP cleaving enzyme) and γ-secretase (the catalytic subunit 
is referred to as PS1) (Fig.1). Initially, APP is cleaved at the N-terminus by β-secretase, thus 
releasing the secreted APPβ (sAPPβ) fragment. Thereafter, Aβ shedding occurs, whereby γ-
secretase cleaves the remaining C-terminus of APP to release the small Aβ fragment into the 
extracellular environment (Caetano et al., 2011) (Fig.1). Under standard physiological 
conditions, APP is processed through the non-amyloidogenic pathway. In this context, APP is 
cleaved, initially by α-secretase to produce sAPPα (which precludes Aβ formation), 
thereafter, by γ-secretase to finally produce p3. Although the physiological functions of these 
products are not well understood, it is suggested that sAPPα has growth promoting functions, 
whereby it plays a role in the development of the brain. In addition, sAPPα may enhance 
neurite growth, improve the formation of memories and contribute to pro-survival pathways 
(review see Chow et al., 2010). AD occurs when the amyloidogenic pathway is 
inappropriately favoured and when Aβ42 degradation is reduced, thus leading to accumulation 
of these peptides (Kakiya et al., 2012).  It is proposed that the mechanism by which Aβ 
prompts the characteristic neuronal loss is due to its interaction with specific cell components 
(Verdier & Penke, 2004; Da Costa Dias et al., 2011). This occurs when the Aβ either directly 
interacts with receptors on the cell surface (Da Costa Dias et al., 2011) or through indirect 
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interactions, such as incorporation into cell organelles and lipid membranes (Verdier & 
Penke, 2004). These processes modify signal transduction pathways, such as disruptions in 
cholinergic systems (Kelly et al., 1996) consequently causing synaptic dysfunction and 
neuronal death. The core component of amyloid plaques is the Aβ42 peptide, it has a higher 
propensity to aggregate (Jarrett et al., 1993) and is known to be more neurotoxic (Saido, 
1998) than its 40 amino acid (Aβ40) counterpart, which is predominant in non-diseased 
brains. The plaques themselves are thought to not directly cause the AD pathology but rather, 
the pathology occurs as a consequence of Aβ-mediated distortions in the neural morphology. 
These distortions impede neurotransmission and correspondingly, cause neural dysfunction 
(Hyman et al., 1995). Instead, it is the soluble Aβ oligomers which are accepted as the 
pathological agent due to their neurotoxicity, caused by their functional role in forming ion-
permissible channels in the cell membrane. Ultimately, resulting in an influx of ions, 
specifically Ca2+, with subsequent cytotoxicity (Lin et al., 2001; Demuro et al., 2005). Aβ 
neurotoxicity has therefore been linked to Aβ-induced neuronal apoptosis through this 
disruption in cellular calcium homeostasis as well as oxidative stress, both of which 
contribute to mitochondrial dysfunction (Mattson, 1997) and DNA damage (Zhang et al, 
1995; Deng et al, 1999).  
 
 
Fig. 1: Schematic of the processing 
of APP and the cleavage products. 
Pathway of non-amyloidogenic 
processing of APP (right/blue) involves 
cleavage by α- and γ-secretases 
generating the secreted form of APP 
(sAPPα) and C-terminal fragments (CTF 
83, p3 and AICD50). Pathway of 
amyloidogenic APP processing (left/red) 
involves cleavage by β- and γ-secretases 
generating the secreted form of APP 
(sAPPβ), C-terminal fragments (CTF 99 
and CTF 89) and Aβ. (Adopted directly 
from Chow et al., 2010) 
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However, additional aspects, which contribute to AD include: lipid oxidation, oxidative stress 
and protein degradation, all of which are attributed to the abovementioned interaction 
between Aβ and cell surface receptors (Bartzokis, 2011; Marchesi, 2011; Da Costa Dias et 
al., 2011). This interaction results in the internalisation of Aβ42, thus causing the intracellular 
accumulation of Aβ42, which directly corresponds with the progression of AD (Stefani, 
2010). Once Aβ42 is internalised, aggregation of the Aβ42 oligomers occurs, subsequently 
resulting in the aforementioned disturbance in cell signalling, dysfunction of normal cellular 
processes and cellular damage, eventually causing cell death (Mucke & Selkoe, 2012). 
One of the receptors in AD which interacts with Aβ, is the 37kDa Laminin Receptor 
Precursor/67kDa high affinity Laminin Receptor (LRP/LR) (Da Costa Dias et al., 2013).  
1.3. The 37 kDa Laminin Receptor Precursor/ 67 kDa high affinity Laminin Receptor 
(LRP/LR) and its role in Alzheimer’s disease. 
LRP/LR, otherwise known as LamR1, RPSA and p40 is a multifunctional type II 
transmembrane receptor consisting of 295aa and is predominantly found within lipid raft 
regions of the plasma membrane, however, it also exists within the cytoplasm and the nucleus 
(Mbazima et al., 2010). It was suggested that the 37 kDa LRP gives rise to the 67 kDa LR, 
however, it is now understood that the 67 kDa LR is not a homodimer of the 37 kDa LRP 
(Hundt et al., 2001) but rather, it is a result of post-translational modifications (Landowski et 
al., 1995). LRP/LR has a substantial physiological role in both normal and cancerous cells. 
This is due to the interactions of LRP/LR as a receptor in the extracellular environment, 
whereby it binds to elastin, laminin-1, heparin sulfate proteoglycans (HSPGs), prion proteins- 
(PrPc and PrPSc) (Gauczynski et al., 2006) and Aβ (Jovanovic et al., 2015). In the intracellular 
environment, LRP/LR interacts with histones (Kinoshita et al., 1998) to maintain nuclear 
structures, it acts as a component of the 40S ribosomal subunit, thereby mediating translation 
(Ford et al., 1999) and it interacts with the cytoskeletal proteins, tubulin and actin 
(Venticinque et al, 2011). This further indicates an integral role in translation and cell 
migration (for review on LRP/LR see Jovanovic et al., 2015; Weiss, 2017). However, it is of 
particular importance, that these interactions associate LRP/LR with numerous diseases. 
These include, but are not limited to, cancer, prion disorders, ageing and AD. In cancer, 
LRP/LR is known to be highly upregulated, leading to enhanced adhesion and invasion and 
ultimately, metastasis, as well as angiogenesis and the inhibition of apoptosis (Rao et al., 
1989; Zuber et al., 2008; Omar et al., 2012; Moodley & Weiss., 2013; Khumalo et al., 2013; 
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Khusal et al., 2013; Chetty et al., 2014; Rebelo et al., 2016; Vania et al., 2016). LRP/LR is 
involved in the ageing process due to an interaction with telomerase (Naidoo et al., 2015; 
Otgaar et al., 2017).  In AD, LRP/LR is implicated through its interaction with Aβ as well as 
the AD-related proteins; APP, γ- secretase and β- secretase (Jovanovic et al., 2014). 
It has been demonstrated that LRP/LR and Aβ co-localise on the cell surface and that 
LRP/LR is a receptor for synthetic Aβ42 peptides (Da Costa Dias et al., 2013). When 
antibody (IgG1-iS18) and small hairpin RNA (shRNA) technologies were employed to target 
LRP/LR, to block the receptor and downregulate its expression, respectively, it was observed 
that both treatments significantly reduced Aβ mediated cytotoxicity and Aβ shedding 
(Jovanovic et al., 2013; Da Costa Dias et al., 2013). With this information, it was discovered 
that LRP/LR is implicated in the pathogenicity of AD and this warranted further study. It was 
observed that the interaction between Aβ42 and LRP/LR on the cell surface inhibits cell 
proliferation and induces apoptosis, as indicated by the presence of apoptotic bodies post-
treatment with cytotoxic levels of Aβ42 peptides (Da Costa Dias et al., 2014). This is due to 
the involvement of LRP/LR in the internalisation of Aβ42, thus resulting in the accumulation 
of Aβ42 intracellularly (Jovanovic et al., 2014) and ultimately Aβ42 mediated cytotoxicity (Da 
Costa Dias et al., 2013). Furthermore, as PrPc binds to both Aβ and LRP/LR, it was 
investigated whether the underlying mechanism of the Aβ42 – induced neuronal cytotoxicity 
was an indirect result of the PrPc - Aβ42 interaction (Pinnock et al., 2016). It was observed in 
vitro that overexpression of PrPc caused a significant enhancement in Aβ42 mediated 
cytotoxicity. However, on blockade of LRP/LR with IgG1-iS18, cell viability was 
significantly increased in PrPc expressing cells but not in PrPc negative cells. Therefore, 
suggesting LRP/LR has a significant function in PrPc -mediated, Aβ42 – induced cytotoxicity 
(Pinnock et al., 2016). Therefore, LRP/LR is pivotal in causing the resultant aforementioned 
harmful cellular effects through the facilitation of the uptake of Aβ42 (Jovanovic et al., 2014). 
In addition, Jovanovic et al, 2014 observed that LRP/LR co-localises with APP, β- and γ –
secretases inside the cell and on the cell surface. Interestingly, both the IgG1-iS18 and 
shRNA treatments do not alter the expression of APP, β- and γ –secretases on the cell surface 
but rather reduce levels of sAPPβ, and the release of Aβ into the extracellular environment 
(Jovanovic et al., 2013; Da Costa Dias et al., 2013). Upon further investigation, the 
interaction between LRP/LR and β – secretase was found to be indirect. However, the 
interaction with PS1, the catalytic subunit of γ-secretase and LRP/LR was established as 
direct and that this interaction enhances cleavage of APP, thus releasing sAPPβ. Therefore, 
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the blockade or knockdown of LRP/LR results in the impediment of β- and γ-secretase 
activity, through the impediment of the interaction between the two, respectively, thereby 
reducing sAPPβ levels and ultimately decreasing Aβ shedding (Jovanovic et al., 2013) 
(Fig.2).  
 
Fig. 2. The effects of anti-LRP/LR specific antibody IgG1-iS18 on the amyloidogenic 
processing of APP. LRP/LR blockade with IgG1-iS18 reduces the amount of sAPPβ and Aβ 
generated. (Adopted directly from Jovanovic et al., 2015). 
Taken altogether, there is a definitive role, which LRP/LR plays in AD. In addition, strategies 
employed to target LRP/LR, inclusive of blockade by the anti-LRP/LR specific antibody, 
IgG1-iS18 and downregulation via anti-LRP shRNA, significantly reduce Aβ shedding as 
well as internalisation. This information is therefore, invaluable in the search and 
development of therapeutics for the treatment of AD.  
1.4. The role of telomerase and telomere biology in Alzheimer’s disease 
1.4.1. Telomerase in the maintenance of telomeric structures 
Recently, an additional protein found to be associated with AD is telomerase, a 
ribonucleoprotein with reverse transcriptase activity, which is principally found in highly 
proliferative cells (Greider & Blackburn, 1987; Kim et al., 1994). Telomerase is a multi-
subunit protein but has two key components (Fig. 3). The catalytic subunit, the telomerase 
reverse transcriptase, TERT and the telomerase RNA component (TERC), serving as the 
RNA template, utilized by TERT to extend telomeres (Nakamura and Cech, 1998). 
Telomerase has a key function in protecting DNA from degradation, through the addition of 
telomeric (TTAGGG) repeats to the ends of telomeric DNA in a 3ʹ- 5ʹ direction (Fig. 3). 
Therefore, the principal function of telomerase is to maintain and elongate telomeres (Greider 
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& Blackburn, 1987; Kim et al., 1994).This function of telomerase is essential  due to the “end 
replication problem”, which occurs as a result of the semi-conservative mechanism of DNA 
polymerase (Lingner & Cech, 1998).TERT serves as the limiting factor of telomerase 
activity, as the activity is directly dependent on the amount of TERT present (Bodnar et al., 
1998; Counter et al., 1998).  
Telomerase activity has a key role in cellular senescence and immortalisation, it therefore, 
plays a significant role in the ageing process and the cancerous state (Shay & Wright, 2005). 
Cellular senescence occurs as a result of cellular stresses, which include telomere erosion, 
genomic instability and mitochondrial dysfunction. All of which lead to functional decline 
and disruptions in tissue homeostasis due to a limit in the replicative and regenerative 
potential of cells (Allsop & Harley, 1995; Molofsky et al., 2006). Furthermore, in the context 
of cancer, senescence as a result of these stresses is bypassed due to an increase in telomerase 
activity (Shay & Wright, 2005). 
 
Figure 3. Schematic diagram of the multi-subunit protein, telomerase, elongating 
telomeric DNA. Telomere elongation occurs when the two essential subunits, TERT and 
TERC catalyse the addition of TTAGGG repeats to the ends of chromosomes. These are 
indicated in a complex together with the telomerase related proteins, Dyskerin, NHP2, 
NOP10 and GAR which are partly responsible for the stability of the complex, as well as for 
the extra-telomeric functions of telomerase. (Adopted directly from Townsley et al., 2014). 
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1.4.2. Telomerase and its non-telomeric functions: Protection 
There are various extra-telomeric processes in which telomerase plays a part, predominantly 
for the conservation of cell viability (Saretzki, 2014). In addition to its role as the catalytic 
subunit of telomerase, TERT localizes to the mitochondria, whereby it aids in the functioning 
of the organelle, as well as serving a protective purpose (Ahmed et al., 2008; Haendler et al., 
2009; Singhapol et al., 2013). This is evident when reactive oxygen species (ROS) are 
present and conditions become hypoxic, TERT translocates to the mitochondria. Here, TERT 
protects the organelle against mitochondrial DNA (mtDNA) damage, as well as apoptosis 
(Cong & Shay, 2008). Additionally, TERT contributes towards the replication and repair of 
mtDNA, altogether demonstrating TERT is essential to the function of the mitochondria 
(Sharma et al., 2011).  
Furthermore, telomerase has been implicated in DNA repair and DNA damage responses by 
which it is involved in the recruitment of DNA repair proteins (Saretzki, 2014). Moreover, 
there is further evidence to suggest the role of telomerase in DNA repair by the occurrence of 
telomeric repeats at DNA breaks (Cong & Shay, 2008). There are several factors involved in 
the DNA repair process as well as signalling the presence of DNA damage, which 
accumulate at the occurrence of double-stranded DNA breaks. One of particular importance 
is the phosphorylation of histone H2AX (γH2AX) (Paull et al, 2000), which promotes the 
recruitment of repair and damage proteins. It has been elucidated that a lack of hTERT in 
cells, impairs the DNA damage response due to a reduction in the amount of H2AX 
phosphorylation (Masutomi et al, 2005). Therefore, this suggests that hTERT has an essential 
role in regulation of the DNA damage response pathway. 
1.4.3. Telomerase and its non-telomeric functions: Transcriptional regulation 
Additionally, TERT is known to play a role as a transcriptional regulator, whereby it serves 
as a transcriptional activator of numerous genes related to signal transduction pathways 
involved in cell viability as well as development and proliferative processes that are regulated 
by the Myc and Wnt pathways (Choi et al., 2008; Cong & Shay, 2008; Park et al., 2009). 
Thus, indicating a complex set of regulatory processes which occur amongst the 
aforementioned pathways and TERT itself (Choi et al., 2008; Park et al., 2009; Saretzki, 
2014). TERT expression is known to be activated by the transcription factor, Myc and there 
is evidence proposing that a positive feedback loop exists between the two (Choi et al., 2008; 
Park et al., 2009). In addition, TERT plays a regulatory role through an association with the 
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Wnt pathway, whereby both are involved in controlling entry into the cell cycle and 
therefore, proliferation (Cong & Shay, 2008). This occurs as TERT occupies regions on the 
promoters of the genes of the cell cycle transcriptions factors, Myc and cyclin D1 (Yang et 
al., 2008; Li et al., 2011). An alternative mechanism for activation of the Wnt signalling 
pathway is by the transcription factor β-catenin, of which TERT has been shown to act as a 
co-factor, thereby further indicating an involvement in the promotion of cell viability and 
proliferation (Park et al., 2009). Therefore, there is a clear indication that TERT is crucial in 
the regulation of cell survival and proliferative pathways, in addition to its role as the 
catalytic subunit of telomerase. 
1.4.4. The role of telomerase in Alzheimer’s disease 
There is fairly recent evidence that has implicated telomerase in the pathological processes of 
AD (Zhu & Mattson., 2000; Franco et al., 2006; Wang et al., 2015). There is supporting 
evidence which has shown that AD sufferers present shorter telomere lengths in their 
neuronal and T cells (Franco et al., 2006). Furthermore, it has been demonstrated in vitro, 
that telomerase activity is inhibited by Aβ42 and that this occurs when the Aβ oligomers 
physically bind to the telomeric DNA-RNA template complex of telomerase (Wang et al., 
2015), which is indicative of an antagonistic relationship that exists between telomerase and 
Aβ within neurons. Thus, this process actively contributes to the telomere loss experienced 
by AD patients. It has been proposed that an upregulation of telomerase could be a potential 
therapeutic strategy for the treatment of AD as the resulting overexpression of TERT plays a 
protective function against Aβ-induced apoptosis in neuronal cells (Zhu & Mattson., 2000).  
Furthermore, it has been shown that TERT interacts with the tumour suppressor, p53, through 
an interaction with the TERT binding protein, TEP-1 (Li et al., 1999a). p53 is known to 
induce apoptosis through ROS-induced alterations in mitochondrial membrane potential and 
is present at increased levels in amyloid plaque affected neurons (de la Monte et al., 1997), as 
well as in mouse brain tissue overexpressing Aβ (LaFerla et al., 1996). Therefore, TERT is 
involved in modulating apoptotic effects of p53. A novel discovery by Naidoo et al., 2015 
has illustrated that there is both an interaction and co-localisation between LRP/LR and 
hTERT within perinuclear compartments and on the cell surface. In addition, it was shown 
that small interfering RNAs (siRNAs) directed against LRP/LR, facilitating its knockdown, 
resulted in a significant reduction in telomerase activity (Naidoo et al., 2015). Furthermore, 
Otgaar et al., 2017 elucidated that overexpression of LRP::FLAG (Vana & Weiss, 2006) 
resulted in an increase in TERT expression, telomerase activity, telomere length as well as a 
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reduction in senescent markers (Otgaar et al., 2017). Altogether indicating that LRP/LR has a 
role in the regulation of telomerase activity and TERT expression (Naidoo et al., 2015; 
Otgaar et al., 2017). Therefore, employing strategies, such as the overexpression of 
LRP::FLAG, which target LRP/LR, to increase TERT levels and telomerase activity could 
provide a prospective therapeutic strategy for the treatment of AD. 
1.5. Hypothesis 
There is a clear demand for non-palliative therapeutic strategies for AD, this is highlighted by 
the high occurrence of AD, the significant economic cost thereof and due to the current 
availability of treatments being merely palliative in nature. LRP/LR plays an important role 
in facilitating the pathological processes involved in AD. LRP/LR functions as a receptor for 
neurotoxic Aβ peptides and is involved in the amyloidogenic processing of APP, due to its 
interaction with β-and γ-secretase. Furthermore, LRP/LR plays a critical role in the 
internalisation of Aβ and therefore, its accumulation and ultimately the resulting cytotoxic 
effects initiated by Aβ and the related pathways. In addition, telomerase is known to 
contribute to the pathological processes in AD. This is evident in the shortened telomeres of 
AD sufferers, as well as the antagonistic relationship between Aβ42, the aetiological agent of 
AD, and TERT, the reverse transcriptase of telomerase. Moreover, it has been elucidated that 
LRP/LR has a regulatory role in telomerase activity and TERT expression. Furthermore, this 
interaction between LRP/LR and telomerase had been tested in an ageing and a cancer 
context but had yet to be assessed in the context of AD.  
As aforementioned, studies performed on the knockdown and blockade of LRP/LR through 
shRNA and LRP specific antibodies in an in vitro AD model have shown that 
impediment/inhibition of LRP/LR has positive effects on AD pathology. This includes rescue 
from Aβ-mediated cytotoxicity and a significant reduction of Aβ internalisation and 
shedding, thereby suggesting the blockade/knockdown of LRP/LR as a potential therapeutic 
strategy for AD. However, since these studies were performed in vitro, it was of importance 
to continue this study in an in vivo model to further validate this strategy. Therefore, the first 
part of this study included treating AD transgenic mice with IgG1-iS18 and thereafter 
assessing the resulting effects on AD pathology, including the effects on cognitive function, 
AD histopathology and the levels of the AD-related proteins.   
It has been suggested that upregulating TERT could be a potential therapeutic strategy for 
AD, due to the resultant protection from Aβ-induced apoptosis. Therefore, the second part of 
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this study served to assess the effects of overexpressing LRP::FLAG intracellularly, with a 
resultant increase in TERT levels, on cell viability, telomerase activity and Aβ42 levels in in 
vitro AD models. 
2. Aims and objectives 
2.1. Main aim 
To investigate the effect of LRP/LR on Alzheimer’s disease related proteins, TERT 
expression and telomerase activity in vivo with the use of Alzheimer’s disease mice and in 
vitro employing Alzheimer’s disease cell culture models. 
2.2. Specific objectives 
1. To test the efficacy of IgG1-iS18 as a therapeutic for Alzheimer’s disease by performing 
animal studies with AD transgenic mouse models.  
2. To investigate the role of blocking LRP/LR on mTERT levels and telomerase activity in 
AD transgenic mouse models. 
3. To assess the endogenous levels of hTERT and LRP in the neuronal cell line, SH-SY5Y 
via western blotting. 
4. To stably transfect the neuronal cell line, SH-SY5Y with the pCIneo-moLRP::FLAG 
construct to induce overexpression of LRP::FLAG.   
5. To confirm LRP::FLAG transfection by confocal microscopy and western blotting. 
6. To assess the effect of LRP::FLAG overexpression on LRP, hTERT and Aβ localisation 
and levels by confocal microscopy and western blotting.  
7. To assess the effect of overexpressing LRP::FLAG on telomerase activity by qPCR.  
8. To assess the effect of overexpressing LRP::FLAG on cell viability using an MTT assay. 
9. To assess the effect of overexpressing LRP::FLAG on Aβ levels by performing an Aβ-
ELISA. 
10. To investigate whether hTERT and Aβ co-localise by confocal microscopy with the 
addition of Airyscan™. 
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3. Experimental techniques 
3.1. Alzheimer’s disease transgenic mouse study 
The mouse study was carried out by myself and the primary researcher on the project, Dr. Eloise 
van der Merwe. The main aim of the mouse study was to validate the anti-LRP/LR antibody, IgG1-
iS18 as a therapeutic strategy for the treatment of AD. The study began with 24 male 5XFAD AD 
transgenic mice (B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mm; Ethical 
clearance was obtained for these animal trials by the Animal Ethics Screening Committee: 
2014/37/C). These mice contain 5X Familial Alzheimer's Disease (FAD) mutations; three in 
human APP (695) [Swedish (K670N, M671L), Florida (I716V), and London (V717I)] and two in 
human PS1 [M146L and L286V]. The 5XFAD mice, therefore, overexpress mutant human APP in 
the brain and exhibit AD amyloid pathology and are thus useful models of amyloid plaque 
formation and Aβ42 induced neurodegeneration. The 24 5XFAD mice were divided into 2 groups, 
whereby the first group of 12 mice were treated with IgG1-iS18 and the second group of 12 were 
treated with the vehicle only (Phosphate buffered saline - PBS). Treatment was carried out twice a 
week over a period of eight weeks. The mice were first anaesthetized with Isofor in inhalant form 
and then treated via intranasal delivery at the following specified amounts. The first set of 12 mice 
received the IgG1-iS18 treatment antibody at 15 µl per naris (18 µg/ 30 µl/ mouse) twice a week 
(36 µg/ mouse/ week), thereby receiving a total amount of 288 µg of antibody over the eight-week 
period. The control set of 12 mice were given PBS at 15 µl per naris (30 µl/mouse) twice a week 
(60 µl/mouse/week), therefore receiving a total volume of 480 µl over the eight weeks as a vehicle 
control.  
Once treatment was completed, cognitive testing was performed, whereby the novel object 
recognition test, Y-maze test and a puzzle box tests were carried out by Dr. van der Merwe, to 
determine whether those mice treated with the anti-LRP/LR antibody had improvements in 
memory in comparison to the controls. Eight mice from each of the groups were then euthanized. 
Transcardial perfusion was performed with cold PBS (Sigma-Aldrich, St Louis, MO), after which 
the brains were removed and dissected down the midline resulting in two hemispheres of the brain. 
One hemibrain from each mouse was snap frozen in liquid nitrogen then stored at –80 °C until 
biochemical testing was to be performed. The remaining hemispheres were fixed using 4% 
paraformaldehyde overnight, after which they were placed in 30% sucrose for 3 days to displace all 
water from the tissue. Thereafter, the hemibrains were stored at 4 °C in 0.1 M PBS containing 
protease inhibitors. The fixed hemibrains were used to determine the histological effects of the 
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treatment on AD pathology in the brain (IDEXX labs). The frozen hemibrains were used by Dr. 
van der Merwe and myself to perform biochemical studies, including western blotting to assess 
levels of LRP, BACE1, PS1, APP and mTERT, an ELISA to assess levels of soluble Aβ42 and a 
telomerase activity assay.  
3.1.1. Histological analysis: 
Histological analysis was performed by IDEXX laboratories (Pretoria, South Africa). The 
brain samples were re-fixed in 10% buffered formalin and sections were made and processed 
according to routine histological tissue processing in an automated tissue processor with 
standard operating procedures Idexx-AP-SOP-27. Following tissue processing, sections of 5-
6 μm were cut (IdexxSA-AP-SOP-30) and the produced slides were stained in an automated 
Haematoxylin and Eosin tissue stainer (IdexxSA-AP-SOP-205). Slides were furthermore 
stained with Congo red to identify amyloid before histological evaluation. The amyloid load 
was quantified from histological sections by using ImageJ software. Amyloid plaques were 
manually outlined and the amyloid load corresponded to the ratio (%) of the mean area of 
amyloid plaques to total area measured in each hippocampal section. These tests provided 
insight into whether the anti-LRP/LR treated mice had reduced formation of plaques and 
neurofibrillary tangles in comparison to those which received the PBS control treatment. 
3.1.2. Protein extraction: Tissue: 
Mouse hemi-brain homogenates were prepared by first rinsing the brain tissue with 500 µl 
1X PBS (Table S7) containing protease inhibitors (Sigma-Aldrich, St Louis, MO). Thereafter 
the hemi-brains were homogenised in 500 μl cold PBS with protease inhibitors using a 
Dounce homogenizer for 30 s each. From each sample, 100 µl homogenate was removed and 
stored at -20 ⁰C for telomerase activity analysis. To each remaining homogenate, 400 µl of 
2X RIPA lysis buffer (Table S3) was added and incubated at 4 ⁰C for 30 minutes with gentle 
agitation in order to lyse and extract protein fractions from the samples. The lysed samples 
were then centrifuged at 14 000 rpm for 20 min and the supernatant removed and stored at -
20 ⁰C for Western Blot analysis. To the remaining pellet, 100 µl Guanidine HCl buffer 
(GuHCl) (Table S8) containing protease inhibitors (Sigma-Aldrich, St Louis, MO)) was 
added and homogenized to extract the insoluble amyloid beta peptides. Once homogenized, a 
further 7.9 ml GuHCl was added and the samples rotated gently overnight at 4 ⁰C. The 
supernatant was collected and stored at -20 ⁰C until further analysis. A BCA assay was then 
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performed on the RIPA and GuHCl extracted protein samples to quantify the total protein 
concentration for Aβ42 and dot blot analysis, respectively.  
3.1.3. Protein quantification: Bicinchoninic acid assay (BCA): 
The BCA assay allows for protein quantification to ensure accurate and equal loading of 
proteins when performing a western blot. This assay is based on an observable colorimetric 
change of which the absorbance can then be measured using an absorbance 
spectrophotometer. The reaction is based on temperature and the peptide bonds which exist 
within the proteins. These peptide bonds reduce Cu2+ in the copper sulphate reagent which is 
added, to Cu1+. The bicinchoninic acid chelates the Cu1+ which forms a purple product. 
Therefore, the amount of Cu2+ which is reduced is in direct proportion to the number of 
peptide bonds present and therefore, allows for direct quantification of the concentration of 
protein present. 
Briefly, a set of BSA protein standards of known concentrations (0, 0.2, 0.4, 0.6, 0.8 and 1 
mg/ml) were prepared and 10 µl/well of each standard was added to a 96-well plate in 
triplicate. Samples of unknown concentration were added in triplicate, at 3 µl/ well and made 
up to 10 µl with MilliQ water. BCA solution was then made up to 1:30 Copper Sulphate: 
Bicinchoninic acid and thereafter 200 µl of the BCA solution was added to each well, 
including controls, such that the final ratio was 1 part sample to 20 parts BCA solution. The 
samples were then incubated at 37 ⁰C for 30-40 minutes until colour change was sufficient. 
The absorbance was then measured at 562 nm using an ELISA microtiter plate reader. A 
linear regression curve was then calculated for the standards and the concentration of the 
samples calculated using the equation of the curve. Samples were then made up to 5 mg/ml 
for western blot analysis. 
3.1.4. SDS-PAGE and western blotting: 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western 
blotting (WB) were used to detect protein expression levels. This technique was used to 
measure total protein levels of LRP, BACE1, PS1, APP, mTERT and γH2AX in the mouse 
brains.  
The lysates were prepared and quantified as outlined above. The protein samples were heated 
for 5 min at 95°C in Blue Loading Buffer (New England Biolabs) with 40 mM of 
dithiothreitol and a total of 10 μg (β-actin), 20 μg (γH2AX), 25 μg (PS1), 35 μg (LRP), 40 μg 
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(APP), 50 μg (mTERT) and 60 μg (BACE1) of protein was then separated on a Criterion™ 
TGX Stain-Free™ Any kD™ pre-cast gel (Biorad) for 45-55 minutes at 150 V per gel. A 
PageRuler Prestained Protein Ladder (Thermo Fisher) was loaded onto each gel, together 
with the protein samples. Filter papers were soaked in 1X Transfer Buffer (Table S6) and 
PVDF membrane was cut to size and activated in methanol for 5 minutes. The gels were then 
cut to size and 3 layers of filter paper placed on the semi-dry electrophoretic transfer system. 
Membranes were then positioned on the filter papers and the prepared gels placed on top, 
thereafter 3 more layers of filter paper were positioned on top. Furthermore, Transfer Buffer 
was added to the required level and the system closed. Transfer was performed at 300 mA for 
50 minutes. Once transfer was complete, the membranes were blocked in 3% BSA (Amresco) 
in 1X PBS and 0.1% Tween 20 (PBST) for 1 hour. After blocking, primary antibody (Table 
S1) diluted in 10 ml of 3% BSA in PBST was added to the blots and incubated overnight with 
gentle shaking at 4 ⁰C. The membranes were subsequently washed 5 times in PBST for 5 
minutes each with shaking. Secondary antibody (Table S1) diluted in 10 ml 3% BSA in 
PBST was added and the blots incubated for 1 hour in the dark at room temperature with 
shaking. The membranes were then washed 5 times as outlined above. The proteins were 
visualized with Clarity™ Western ECL Blotting Substrate (Biorad) and the ChemiDoc™ 
Imaging System (Biorad). Densitometric analysis was performed with Image Lab 5.1 
software (Biorad), whereby all values were further normalised against the β-actin loading 
control.   
3.1.5. Dot blot analysis:  
A dot blot was performed to determine the effect of IgG1-iS18 treatment on the insoluble Aβ42 
levels. The GuHCl protein extracts were dotted onto a nitrocellulose membrane at 2 µl per 
sample and allowed to dry for 10-15 minutes. The membrane was subsequently blocked in 3% 
BSA in PBST for 30 minutes, where after it was incubated with rabbit anti-human Aβ 1-42 
(Cell Signaling Technology®, D9A3A) (1:1000) at room temperature for 1 hour with gentle 
agitation. The membrane was washed 3 times with PBST for 5 minutes each, with shaking, and 
thereafter incubated with anti-rabbit HRP secondary antibody (Cell Signalling) (1:2500) at 
room temperature for 30 minutes. Once the membrane was washed a further 3 times, as outlined 
above, it was incubated with Clarity™ Western ECL Blotting Substrate (Biorad) and visualized 
with the ChemiDoc™ Imaging System (Biorad). Densitometric analysis was performed with 
Image Lab 5.1 software (Biorad).     
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3.1.6. Amyloid beta enzyme-linked immunosorbent assay (Aβ-ELISA): 
The Aβ- ELISA was used to assess soluble Aβ42 levels in the mouse brain samples. ELISA is 
based on the principle that antibodies have high specificity for their substrates, whereby the 
specific antibody (for the N-terminus of Aβ) is attached to a solid phase, the sample is added 
together with an antibody specific for the C-terminus of Aβ. This step is followed by a wash 
step to get rid of any unbound sample, where after the second antibody is detected through 
the addition of an HRP-conjugated secondary antibody. A wash step is again performed to 
remove any unbound antibody and thereafter the substrate is added to produce a colour 
change, the intensity of the colour is then measured using an ELISA reader. The intensity of 
the coloured product which is formed is in direct proportion to the concentration of Aβ which 
has bound. This was performed with the use of the Human Amyloid β (aa 1-42) Quantikine ® 
ELISA kit by R&D Systems. The manufacturer’s instructions were followed. The plate was 
washed twice with Wash Buffer immediately prior to use. Human Amyloid β (aa1-42) 
standard together with extracted protein samples were added to the wells (100 μl/well) and 
incubated for 2 hours at 4°C. Each well was then aspirated and washed four times with Wash 
Buffer. Cold Human Amyloid β (aa1-42) conjugate (200 μl) was added to each well and 
incubated for 2 hours at 4 °C. The plate was thereafter washed four times with Wash Buffer 
and 200 μl /well of Substrate Solution was added. Following this, the plate was incubated for 
30 min at room temperature in the dark, after which 50 μl/ well of Stop Solution was added.  
The optical density was determined using an ELISA microtiter plate reader at 450 nm with 
wavelength correction at 540 nm. 
3.1.7. Quantitative polymerase chain reaction (qPCR)for detection of telomerase activity: 
Telomerase activity in the mouse brains was quantified with the use of the TRAPeze® RT 
Telomerase Detection Kit. This kit provides a highly sensitive assay for fluorometric 
detection and allows real time quantification of telomerase activity. The principle of the assay 
is based on the telomeric repeat amplification protocol (TRAP) as initially defined by 
Piatyszek et al., (1995).  The TRAPeze® kit makes use of fluorescence energy transfer 
primers (Amplifluor® primers) which provide a way in which to detect and quantify 
telomerase activity by directly measuring real time fluorescence emission. The initial stage of 
the reaction allows telomerase in an extracted sample to add telomeric repeats to the 3ʹ end of 
the substrate over a given time period. Hereafter, the extended products are amplified by Taq 
polymerase, utilising the Amplifluor® primers. These primers only produce a fluorescent 
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signal once they have been incorporated into the telomeric repeat amplification products. The 
amount of TRAP products produced are then directly proportional to the fluorescence 
emission produced. This kit therefore, takes into consideration the real time measurement of 
fluorescence produced which directly allows for relative quantification of telomerase activity 
through the addition of telomeric repeats. 
 Protein and RNA were extracted as per the protocol. Briefly, tissue homogenates were 
resuspended in 200 µl of CHAPS Lysis Buffer/40-100 mg tissue. The suspensions were 
incubated on ice for 30 minutes where after the samples were centrifuged in a 
microcentrifuge at max speed (12 000 x g) for 20 minutes at 4 ⁰C. The supernatants were 
then transferred to clean 1.5 ml Eppendorf tubes and snap frozen on dry ice. The protein was 
then quantified with the NanoDrop® ND-1000 (Thermo Scientific) and standardized to 500 
ng/μl for all experimental and control reactions. OneTaq® HotStart Taq Polymerase (5 U/μl) 
(New England Biolabs) was used as it is not supplied with the kit. All samples were analysed 
via qPCR with the Roche LightCycler LC480 with the following cycling parameters applied: 
One cycle of 37°C for 30 minutes, 95°C for 2 minutes and 45 cycles of 95°C for 15 seconds, 
59°C for 60 seconds and 45°C for 10 seconds. Telomerase activity was thereafter calculated 
from the standard curve generated by 1:10 serial dilutions (20–0.0002 amoles) of the 
provided TSR8 control template as per Merck Millipore instructions. Negative controls were 
included. A minus telomerase control, consisting of only CHAPS Lysis Buffer was used to 
ensure the buffer had not been contaminated and had no telomerase activity. A no template 
control consisting of only Nuclease free/PCR Grade Water was used so as to normalise 
against primer dimer formation of the Amplifluor primers in the absence of telomerase 
activity. Since telomerase is a heat-sensitive enzyme, a heat-treated telomerase negative 
control was also included so as to evaluate each sample for heat sensitivity, whereby 10 µl of 
each 500 ng/µl sample was incubated at 85 ⁰C for 10 minutes prior to detection, in order to 
inactivate telomerase. A telomerase positive cell extract was provided as a positive control 
and made up as per the protocol. The data was then analysed with LightCycler1 Software 
version 1.5.1. All values were normalised against the negative controls, whereby, all negative 
control values (including signals for CHAPS only, no template control and heat-treated, 
respectively) were subtracted from the signal of each sample and thereafter, the mean value 
calculated for all biological repeats. 
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3.2. Alzheimer’s disease in vitro study: 
3.2.1. Cell culture: 
The cell lines used in this study include the SH-SY5Y: Human neuroblastoma cell line as the 
model to mimic AD and the embryonic HEK293: Human embryonic kidney cell line as a 
TERT and telomerase positive control. The SH-SY5Y and HEK293 cells were cultured in 1:1 
Dulbecco’s Modified Eagle Medium and Ham’s F12 nutrient mixture supplemented with 
15% Foetal Bovine Serum for additional nutrients and 1% penicillin/streptomycin mixture for 
bacterial contamination control. The media supplies all the necessary nutrients for the cell 
lines to grow optimally. Cells were incubated at 37 ᵒC with 5% CO2 in a humidified 
atmosphere to mimic in vivo conditions. Nutrient medium was replenished when necessary 
and cells were sub-cultured at least once a week. Prior to subculturing PBS and the culture 
media were allowed to come to room temperature. Subculturing included washing the cells 
with 5 ml 1X PBS for 1 minute and were then incubated with 2 ml Trypsin/EDTA for 5 
minutes at 37 ᵒC to remove the cells from the cell culture flask. Once the cells had detached, 
8 ml of supplemented growth media was added to inactivate the Trypsin/EDTA. Thereafter, 
2-8 ml of this cell suspension was added to a total volume of 10 ml in 75 cm3 flasks. 
3.2.2. Transfection: 
This component included stably transfecting SH-SY5Y and HEK293 cells with an 
LRP::FLAG construct (pCIneo-moLRP::FLAG) to induce overexpression of LRP. 
Transfection was carried out in a T25 flask (25 cm2) once cells had reached 50-70% 
confluency, following the Clontech Xfect™ transfection protocol. Briefly, 10 µg pCIneo-
moLRP::FLAG plasmid DNA was added to 200 µl Xfect reaction buffer, where after 3 µl 
Xfect Polymer was added. This solution was resuspended and incubated at room temperature 
for 10 minutes to allow nanoparticle complexes to form. Thereafter, the nanoparticle 
complexes containing the plasmid DNA were added to the subconfluent cell culture and 
incubated for 48 hours at 37 ⁰C and 5 % CO2 in a humidified atmosphere. All growth media 
was then removed and replaced with fresh complete growth media. Transfected cells were 
subsequently treated with 800 ng/ml Geneticin, 48 hours post-transfection as a selective 
treatment and thereafter at 400 ng/ml to maintain the transfected cell population until a stable 
transfection was achieved.  This was performed to investigate the consequential effects of 
overexpressing LRP::FLAG on telomerase activity, hTERT expression, Aβ expression as 
well as the effects on Aβ-mediated cytotoxicity. 
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3.2.3. Confocal microscopy with Airyscan™: 
Confocal imaging allows one to take images of fluorescently labelled molecules both on and 
inside cells at a very high resolution. The Airyscan™ allows for 1.7X higher resolution in a 
three-dimensional view thus resulting in a 5X smaller confocal volume, with a resolution of 
approximately 140 nm. Confocal microscopy with the addition of Airyscan™ was used to 
detect localisation and expression levels of LRP::FLAG, LRP, hTERT and Aβ42 in both the 
non-transfected and transfected SH-SY5Y cells. Cells were seeded at a density of 1.2 x105 
cells/well onto cover glass (Labocare – 18X18 mm; 0.19 mm thick) in a 6-well plate and 
incubated overnight at 37 ⁰C and 5 % CO2 in a humidified atmosphere. All subsequent steps 
were performed with gentle shaking. Cells were washed once in 1ml 1X PBS for 5 minutes, 
subsequently, cells were fixed in 2 ml fresh 4 % formaldehyde for 20 minutes at room 
temperature. Cells were washed as above and thereafter permeabilised in 3 ml 0.25 % Triton 
X-100 for 30 minutes. Cells were washed 3 times as above and blocked in 2 ml 0.5 % BSA in 
1X PBS for 30 minutes then washed once. Cells were then incubated with the relevant 
primary antibody diluted (1/200) (Table S2) in 500 µl fresh 0.5 % BSA in 1 X PBS overnight 
at 4 ⁰C. Hereafter, cells were washed 3 times as above for 5 minutes each in fresh 0.5 % BSA 
in 1X PBS. Cells were then incubated with the respective secondary antibody diluted (1/500) 
(Table S2) in 500 µl 0.5 % BSA in 1 X PBS for 2 hours in the dark at room temperature. 
Coverslips were then rinsed 3 times as above, in the dark and thereafter incubated in 1 ml 
0.05 µg/ml DAPI diluted in 1X PBS for 5 minutes in the dark. Coverslips were then rinsed 4 
times as above and mounted onto glass microscope slides with 20 µl Sigma Fluoromount 
(Sigma) and allowed to set in the dark at room temperature for 1.5 hours. Thereafter, slides 
were stored in the dark at 4 ⁰C until viewed.  
3.2.4. Protein extraction from cells: 
Cell lysates were prepared by first harvesting cells. Growth media was removed from the 
flasks containing the relevant cell lines, cells were then washed with 5 ml 1X PBS. 
Thereafter, cells were removed from the culture flasks by the addition of 2 ml Trypsin/EDTA 
with incubation at 37 ⁰C for 5 minutes. Culture media was then added at 8 ml per flask to 
inactivate the Trypsin/EDTA and the cell suspension was transferred to 15 ml Falcon tubes 
and centrifuged at 5500 rpm for 10 minutes. The supernatant was removed and 200 -300 µl 
1X RIPA buffer was added dependent on the cell pellet size. The cells were resuspended in 
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the RIPA buffer and then incubated at 4 ⁰C for 15 minutes. A BCA assay was then performed 
to determine the total protein concentration for western blot analysis.  
3.2.5. Protein quantification: 
Protein quantification on all cell lysates was performed using the BCA assay as stated in 
3.1.3, after which these samples were standardised to a concentration of 2 mg/ml for WB 
analysis. 
3.2.6. SDS-PAGE and western blot: 
SDS-PAGE and WB was carried out on the cell samples to assess levels of LRP and hTERT 
in both the non-transfected and LRP::FLAG transfected SH-SY5Y and HEK293 cells.  This 
was performed as mentioned above in section 3.1.4, whereby 10 μg (β-actin and LRP) and 50 
μg (hTERT) of protein was resolved on a 12% SDS-PAGE gel (Table S4). 
3.2.7. 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT) cell viability 
assay: 
The MTT assay was used to assess cell viability once the SH-SY5Y and HEK293 cells were 
confirmed to be expressing LRP::FLAG, following transfection. This assay allowed the 
determination of whether overexpressing LRP might rescue cells from Aβ-mediated 
cytotoxicity. 
This assay is based on a colorimetric effect produced as a result of NAD(P)H –dependent 
oxidoreductases being present in the cell and thus indicating metabolic activity as a direct 
reflection of cell viability (Mosmann, 1983). Mitochondrial Succinate Dehydrogenase, which 
is present in viable cells, is able to reduce the tetrazolium dye, MTT (3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide) to its insoluble form, causing the 
formation of purple formazan crystals. The quantity of crystals formed directly indicates 
cellular viability and therefore, delivers a means of quantifying cell viability in relation to an 
untreated sample.  
Briefly, non-transfected and LRP::FLAG transfected HEK293 and SH-SY5Y cells were 
seeded at 1 x 105 cells/well in a 48 well plate and incubated overnight under normal 
conditions to allow attachment. Following this, the cells were treated with 500 nM Aβ/ml (to 
mimic Aβ-mediated cytotoxicity) and after 48 hours, 100 µl of 1 mg/ml MTT was added to 
each well and incubated for 2 hours at 37 ⁰C. The resultant formazan crystals were dissolved 
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in 200 µl DMSO and resuspended, thereafter the optical density was determined using an 
ELISA plate reader at 570 nm. Those cells which are able to reduce the MTT to form the 
formazan crystals have a higher cell viability. 
3.2.8. Amyloid beta enzyme-linked immunosorbent assay (Aβ1-42-ELISA). 
The Aβ- ELISA was used to assess intracellular Aβ42 levels and internalisation of Aβ42 upon 
overexpression of LRP::FLAG in the HEK293 and SH-SY5Y cell lines. Protein lysates were 
prepared (3.2.4; 3.2.5), and the Aβ- ELISA was performed as outlined above (3.1.6). 
3.2.9. Quantitative polymerase chain reaction (qPCR) for detection of telomerase activity. 
Telomerase activity in the LRP::FLAG transfected SH-SY5Y and HEK293 cell lines was 
quantified with the use of the TRAPeze® RT Telomerase Detection Kit. Protein and RNA 
were extracted as per the protocol, cell pellets were resuspended in 200 µl of CHAPS Lysis 
Buffer/ 105-106 cells and the protocol completed as in (3.1.7). 
3.3. Statistical analysis:  
Statistical analysis for both the in vivo and in vitro studies was performed using Microsoft 
Excel 2010 (Microsoft Corporation) and QuickCalcs Outlier Calculator ©2017 GraphPad 
Software which employs the Grubbs' test (extreme studentized deviate). All experiments 
were performed with a minimum of three biological repeats with error bars representing 
standard deviation. The Student’s t-test was performed at a 95% confidence interval; where p 
values < 0.05 were considered statistically significant (*p < 0.05, **p < 0.01 and ***p < 
0.001).  
4. Results 
4.1. Alzheimer’s disease transgenic mouse study 
To validate whether targeting LRP/LR using IgG1-iS18, in 5XFAD transgenic mice, would 
influence their cognitive abilities, the novel object recognition and puzzle box tests were 
performed by Dr. E. Ferreira- van der Merwe. The novel object recognition test was used to 
evaluate the effect of treatment with IgG1-iS18 on recognition memory in comparison to PBS 
treated control mice. Dr. Ferreira-van der Merwe observed that the treated mice exhibited 
object recognition by preferentially exploring the novel object (58.09%) compared to the 
familiar object (41.91%) during the testing phase (Fig. S1A). To further investigate the short 
and long-term memory as well as learning ability of the AD transgenic mice, Dr. Ferreira-van 
der Merwe performed the puzzle box test. Here, the data suggested that IgG1-iS18 
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significantly improved short term memory as well as learning ability (Fig. S1B). Therefore, 
overall, it was observed there was a significant improvement in short term and learning 
memory after intranasal treatment with IgG1-iS18 (Ferreira, Bignoux, Otgaar, et al. 
Oncotarget, in press). 
 
To further validate IgG1-iS18 as a potential therapy for the treatment of AD, 16 AD 
transgenic mice (8 treated with IgG1-iS18 and 8 treated with PBS) were sacrificed at 9 
months of age to perform immunohistochemical studies and biochemical testing. Refer to 
Fig. 4 for an overview of the design of the in vivo study. These tests and all further data 
analysis were performed by both Dr. Ferreira-van der Merwe and myself. 
 
 
Fig. 4: Design of the Alzheimer’s disease in vivo study. A brief outline of the experimental 
procedures performed to assess the efficacy of IgG1-iS18 as a therapeutic for AD in 5XFAD 
AD transgenic mouse models.   
 
4.1.1. Treatment with IgG1-iS18 decreases AD histopathological hallmarks  
Considering the improvement in memory after treatment with IgG1-iS18, we decided to 
investigate the effect on the histopathology of the hippocampus of the AD mice. 
Histopathological analysis of the hippocampus region of the brains of the IgG1-iS18 and PBS 
36 
 
treated mice was performed using the Congo red stain. Images were taken at 400 X 
magnification, Aβ plaques are stained red and amyloid load was quantified using ImageJ 
software. 
 
Fig. 5: Congo red stain of the hippocampus of AD transgenic mice treated with A) PBS 
and B) IgG1-iS18. Magnification at 400 X. C) Amyloid load (%) is expressed as the proportion (%) 
of tissue area occupied by amyloid beta plaques in the hippocampal sections of the PBS and IgG1-
iS18 treated mice. A decrease in amyloid plaque and vacuole formation is observed after treatment 
with IgG1-iS18. Error bars represent standard deviation, n=7. *p, 0.05, **p, 0.01, ***p, 0.001; 
Student’s t-test. (Adapted from Ferreira, Bignoux, Otgaar, et al. Oncotarget, in press). 
Quantitative and post hoc analysis of amyloid load (%) in hippocampal regions of the mouse 
brains was performed. It was determined that the IgG1-iS18 treated mice [Fig. 5B (Mean = 
37 
 
0.64%, SD = 0.32%)] presented a significantly lower [F (1, 12) = 25.08, p = 0.00031] 
amyloid load (Fig. 5C) when compared to the hippocampal regions of PBS treated mice 
[Fig.5A (Mean = 1.52%, SD = 0.33%)].  
4.1.2. Intranasal administration of IgG1-iS18 decreases soluble and insoluble Aβ levels in 
brains of AD transgenic mice  
Since a significant decrease in amyloid plaque formation was seen upon histopathological 
analysis, we thereby wanted to confirm the effect of the IgG1-iS18 treatment on the Aβ 
protein levels. Therefore, we quantified Aβ42 protein levels in the contralateral hemispheres 
of both treatment groups by performing dot-blot analysis of GuHCl-soluble (insoluble) 
(Fig.6A) and an Aβ1-42-ELISA on the Tris-soluble (soluble) (Fig. 6B) samples. 
 
Fig. 6: Levels of Aβ in the brain tissue of AD transgenic mice after treatment with IgG1-
iS18 and PBS. (A) Insoluble Aβ levels were determined by dot blot and calculated as a percentage 
per mg brain tissue. Data shown (average ± standard deviation) is representative of eight biological 
repeats (performed in duplicate) per treatment group. *p, 0.05, **p, 0.01, ***p, 0.001; Student’s t-
test. (B) Levels of soluble Aβ42 in brain tissue of AD transgenic mice after treatment with IgG1-iS18 
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and PBS as determined by Aβ42 ELISA. Data shown (average ± standard deviation) was calculated as 
pg Aβ42 per mg total protein and is representative of seven biological repeats (performed in duplicate) 
per treatment group. *p, 0.05, **p, 0.01, ***p, 0.001; Student’s t-test. (Adapted from Ferreira, 
Bignoux, Otgaar et al. Oncotarget, in press). 
Upon dot-blot analysis, it was shown that IgG1-iS18 treated mice exhibited a significant 24% 
decrease (p=1.55E-05) in insoluble Aβ42 levels per mg of brain tissue when compared to the 
PBS control (Fig.6A). In addition, ELISA analysis of the soluble Aβ42 levels revealed that the 
antibody treated mice hemi-brain homogenates contained an average of 227.71 pg Aβ42 /mg 
total protein, whereas the PBS control hemi-brain homogenates contained an average 370.21 
pg Aβ42 /mg total protein. This presented a significant decrease of 38.49 % (p=2.46E-06) in 
soluble Aβ42 levels in the brains of the mice treated with IgG1-iS18 (Fig.6B). Altogether, this 
data coincides with the data presented upon histopathological analysis (Fig. 5), whereby the 
antibody treatment showed a significant reduction in amyloid plaque formation. 
4.1.3. Treatment with IgG1-iS18 significantly increases APP levels 
Since it was formerly reported that LRP, β-secretase, γ-secretase and APP levels were not 
affected upon treatment with IgG1-iS18 in vitro (Jovanovic et al., 2013), we therefore wanted 
to confirm whether the levels of these proteins had indeed remained unchanged in the brains 
of both treatment groups. Thus, we examined these levels via western blot with subsequent 
densitometric analysis. 
    
Fig. 7: Western blot analysis 
of LRP/LR, β- and γ-secretase 
protein levels in brain tissue of 
AD transgenic mice after 
treatment with IgG1-iS18 and 
PBS. No significant difference in 
LRP/LR, β- and γ-secretase protein 
levels were observed. Error bars 
represent standard deviation, n= 8.  
(Adapted from Ferreira, 
Bignoux, Otgaar et al. 
Oncotarget, in press). 
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Since IgG1-iS18 merely blocks the interaction between LRP and the β -, γ-secretases 
respectively, we expected that this would not affect the respective protein expression levels 
(Jovanovic et al., 2014). As anticipated, we found no significant difference in the levels of 
LRP, β-secretase and γ-secretase when comparing the levels of the respective proteins in the 
hemi-brain homogenates of the antibody treated and PBS treated mice (Fig. 7). However, in 
contrast to what was previously observed in vitro, we found APP levels to be significantly 
higher on average (85.86%; p=4.94E-06) in the hemi-brain homogenates of the IgG1-iS18 
treated mice when compared to the APP levels in the brains of the PBS control mice (Fig. 8). 
Therefore, we suggest this finding in the in vivo study to be attributed to a reduction in 
cleavage of this protein by β- and γ-secretase as due to the reduced interaction between LRP 
and the secretases, as there is a concomitant reduction in Aβ42 levels (Fig. 6)  
 
Fig. 8: Western blot analysis of APP levels in brain tissue of AD transgenic mice after 
treatment with IgG1-iS18 and PBS. A significant increase in APP levels was observed after 
treatment with IgG1-iS18. Error bars represent standard deviation, n=8. *p, 0.05, **p, 0.01, ***p, 
0.001; Student’s t-test. (Adapted from Ferreira, Bignoux, Otgaar et al. Oncotarget, in press). 
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4.1.4. IgG1-iS18 treatment substantially increases mTERT expression and phosphorylation of 
H2AX 
As aforementioned, LRP/LR co-localises with the telomerase reverse transcriptase, TERT 
(Naidoo et al., 2015) and TERT has been reported to play a neuroprotective role (Zhu et al., 
2001). Thus, we resolved to assess whether treatment with the IgG1-iS18 antibody affected 
the levels of mTERT in the mouse brain.  
 
Fig. 9: Levels of mTERT in brain tissue of AD transgenic mice after treatment with 
IgG1-iS18 and PBS. Western blot analysis was performed and a significant increase in mTERT 
levels was observed after treatment with IgG1-iS18. Error bars represent standard deviation, n=8, *p, 
0.05, **p, 0.01, ***p, 0.001; Student’s t-test. (Adapted from Ferreira, Bignoux, Otgaar et al. 
Oncotarget, in press. 
Upon performing a western blotting to detect mTERT levels, with subsequent densitometric 
analysis, it was revealed that mTERT levels in the antibody treated mouse brain samples 
were significantly higher (74.34%; p= 8.14E-11) on average, than the mTERT levels in the 
brains of the control mice (Fig. 9). This data, together with the reduction in amyloid plaque 
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formation (Fig. 5), Aβ42 levels (Fig. 6) and the increase in cognitive function (Fig. S1) in 
IgG1-iS18 treated mice, indicate a possible neuroprotective role of TERT.  
 
Subsequently to having observed an increase in mTERT levels, qPCR analysis was 
performed to assess whether there was a difference in the activity of telomerase, since TERT 
is the catalytic subunit responsible for the reverse transcriptase activity of telomerase. 
 
Fig. 10: Telomerase activity in mouse brains after treatment with PBS and IgG1-iS18. 
Telomerase activity in the mouse brains was compared to telomerase positive HEK293 cells and is 
almost negligible compared to the HEK293 control. No significant difference in telomerase activity in 
brains of AD transgenic mice was observed after treatment with IgG1-iS18. All values were 
normalised against the negative controls; all negative control values were subtracted from the signal 
of each sample. This data is representative of the mean value obtained across all biological repeats for 
each treatment and the HEK293 cells. Error bars represent standard deviation, n=8 per treatment 
group; n=6 for HEK293 samples.   (Adapted from Ferreira, Bignoux, Otgaar et al. Oncotarget, 
in press). 
Although TERT levels increased significantly, there was no significant difference observed in 
telomerase activity between the two treatment groups (Fig. 10). In fact, telomerase activity in 
the brains of the mice was almost negligible when compared to the telomerase positive, 
HEK293 cells. This is conducive to reports showing that adult mouse brains lack telomerase 
activity (Klapper & Mattson, 2001) 
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Since we know that DNA damage plays a key role in the aging process and that it is proposed 
there is a possible involvement of a DNA repair defect in the pathogenesis of AD (Coppede 
& Migliore, 2009), we decided to further validate the neuroprotective role of IgG1-iS18 and 
assess the resultant effect on the DNA damage response by investigating the levels of 
phosphorylated H2AX (γH2AX). These histones are phosphorylated at Ser139 at the 
occurrence of DNA double stranded breaks and serve to marks sites of DNA damage as well 
as to aid in the recruitment of DNA repair factors (Odell et al., 2013). Therefore, we 
performed western blotting and subsequent densitometric analysis on the levels of γH2AX in 
the extracted samples from the hemi-brains of the IgG1-iS18 and PBS treated mice. 
 
Fig. 11: Effect of IgG1-iS18 on phosphorylated (SER139) γH2AX protein levels in brain 
tissue of AD transgenic mice as detected by western blot analysis. A significant increase in 
PSER139 γH2AX levels was observed after treatment with IgG1-iS18. No significant difference is 
observed in H2AX levels. Error bars represent standard deviation, n=7. *p, 0.05, **p, 0.01, ***p, 
0.001; Student’s t-test. (Adapted from Ferreira, Bignoux, Otgaar et al. Oncotarget, in press). 
A significant increase (p=0.006) of 10% (on average), in the γH2AX levels in the antibody 
treated hemi-brain homogenates was observed compared to the PBS control treated mice 
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(Fig. 11). Furthermore, there was no significant change in total H2AX levels between IgG1-
iS18 treated mice and the control mice. Therefore, these results suggest an increase in the 
activation of the DNA repair process, reflected by the significant increase in γH2AX levels. 
4.2. Alzheimer’s disease in vitro study 
Since it was suggested that an upregulation of TERT expression may be a possible strategy 
towards combatting AD (Wang et al., 2015) and that overexpression of LRP::FLAG causes 
an increase in hTERT expression (Otgaar et al.,2017), this part of the study focussed on 
stably transfecting HEK293 and SH-SY5Y cells with the pCIneo-moLRP::FLAG construct. 
Thereafter, the aim was to assess whether inducing overexpression of LRP::FLAG would 
offer a novel and potential therapeutic strategy for the treatment of AD. Refer to Fig. 12 for 
an overview of the design of the in vitro study. 
 
 
Fig. 12: Design of the Alzheimer’s disease in vitro study. A brief outline of the 
experimental procedures performed to assess the effect of LRP::FLAG overexpression in 
HEK293 and SH-SY5Y Alzheimer’s disease cell culture models. 
 
4.2.1. Endogenous levels of LRP and hTERT in HEK293 and SH-SY5Y cells 
Firstly, endogenous levels of LRP and hTERT were assessed via western blotting, in the SH-
SY5Y in vitro AD model and compared to the respective levels in the telomerase/hTERT 
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positive HEK293 control cells. This was to determine whether the SH-SY5Y cell line would 
provide a suitable model for the overexpression study. 
 
 
Fig. 13: Endogenous protein levels of LRP and hTERT in SH-SY5Y and HEK293 cells. 
Levels of LRP and hTERT are significantly lower in the SH-SY5Y cells when compared to HEK293 
cells. Error bars represent standard deviation, n=3 biological repeats (only 2 repeats shown), *p, 0.05, 
**p, 0.01, ***p, 0.001; Student’s t-test. 
SH-SY5Y cells exhibit significantly lower endogenous levels of LRP (p=0.00729) and 
hTERT (p=0.001) levels compared to the respective levels in the HEK293 cells (Fig. 13). 
Thus, the study was continued with the use of the SH-SY5Y cells as the experimental cell 
line and the HEK293 cells as the TERT/telomerase positive control cell line.  
4.2.2. LRP::FLAG overexpression significantly increases LRP levels 
The SH-SY5Y cell line would provide a suitable model for overexpressing LRP::FLAG to 
assess the resultant effects of this potential therapeutic in an AD context. Therefore, the SH-
SY5Y cells were transfected with the pCIneo-moLRP::FLAG construct and selectively 
treated for a period of 6 weeks to induce a stable transfection and overexpression of the 
LRP::FLAG protein. After this period, western blotting was used to detect whether the 
transfection was successful and thereafter to determine whether there was a subsequent 
increase in LRP levels in the HEK293 and SH-SY5Y cells. 
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Fig. 14: Western blot analysis reveals that LRP::FLAG overexpression increases total 
LRP levels in HEK293 and SH-SY5Y cells. A significant increase in LRP levels was observed 
after stable transfection of HEK293 and SH-SY5Y cells with LRP::FLAG. (A) LRP::FLAG (HRP) is 
detected in HEK293 transfected cells and not in non-transfected HEK293 cells. LRP (HRP) 
expression is increased in transfected HEK293 cells. β-actin (HRP) is used as the loading control. (B) 
LRP::FLAG (Cy3) is detected in SH-SY5Y transfected cells and not in non-transfected SH-SY5Y 
cells. LRP (HRP) expression is increased in transfected SH-SY5Y cells. β-actin (HRP) is used as the 
loading control (C) Densitometric analysis indicates a significant 58 % increase in LRP protein level 
after LRP::FLAG transfection in HEK293 cells. (D) Densitometric analysis in SH-SY5Y transfected 
cells indicates LRP::FLAG overexpression significantly increases LRP protein levels by 165 %.  
Error bars represent standard deviation, n=3 biological repeats. *p, 0.05, **p, 0.01, ***p, 0.001; 
Student’s t-test. 
Here, it is shown that LRP::FLAG is exclusively expressed in the transfected HEK293 
(Fig.14A) and SH-SY5Y (Fig. 14B) cells and not in the respective non-transfected cells. In 
addition, it was confirmed that LRP::FLAG overexpression did indeed increase total LRP 
protein levels. Moreover, upon densitometric analysis of the western blots comparing non-
transfected and LRP::FLAG transfected cells, it was revealed that LRP::FLAG 
overexpression significantly increases LRP levels by 58 % (p= 0.0106) in HEK293 cells 
(Fig.14C) and by 165 % (p= 0.014) in SH-SY5Y cells (Fig. 14D). 
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4.2.3. Immunofluorescence microscopy with Airyscan™ reveals that overexpression of 
LRP::FLAG decreases Aβ levels with a concomitant increase in hTERT levels 
Since it was shown via western blotting that the SH-SY5Y cells transfected with LRP::FLAG 
were indeed expressing LRP::FLAG and that there was a resultant increase in LRP levels, 
confocal microscopy was used to further confirm this. As such, confocal microscopy with the 
addition of Airyscan™ was used to firstly, confirm LRP::FLAG expression in the transfected 
SH-SY5Y cells and thereafter to assess the resultant effects on the levels and co-localisation 
of LRP, Aβ42 and hTERT. Furthermore, this was not performed in the HEK293 cells as levels 
and localisation of these proteins were previously reported (Naidoo et al., 2015; Otgaar et al., 
2017; Da Costa Dias et al., 2013). 
 
Fig. 15. LRP::FLAG overexpression decreases Aβ levels in SH-SY5Y cells. (A-L). 
Intracellular localisation and co-localisation of LRP (FITC-Green) and Aβ (APC-Red) as well as 
LRP::FLAG (FITC-Green) and Aβ in non- and LRP::FLAG transfected SH-SY5Y cells. (A). 
Endogenous LRP levels in SH-SY5Y cells, LRP localises to cytosol and cell surface. (B) Endogenous 
Aβ levels in SH-SY5Y cells, Aβ is localised to cytosol and cell surface. (G) LRP levels are increased 
in LRP::FLAG transfected cells. (H) LRP::FLAG expression is confirmed in transfected SH-SY5Y 
cells and localisation occurs predominantly on the cell surface and cytoplasm. (I) Aβ expression 
becomes almost undetectable upon overexpression of LRP::FLAG. (C&J) Nuclei are stained with 
DAPI [Blue]. Co-localisation occurs between LRP and Aβ both inside the cell and on the cell surface, 
represented by yellow fluorescence in merged images (D&K), as white areas (E) and as fluorescence 
in the third quadrant of the 2D cytofluorograms (F&L). All images are at 630 X magnification and a 
resolution of 140 nm. Scale bars represent 10 µm. 
In non-transfected SH-SY5Y cells, LRP localises on the cell surface and intracellularly (Fig. 
15A), as previously reported in (Mbazima et al., 2010). Under the same conditions, Aβ tends 
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to localise to the cell surface as has been shown previously (Vetrivel &Thinakaran, 2010) and 
to a lesser extent in the cytoplasm (Fig.15B). Here, we see a low level of co-localisation (Fig. 
15E) between LRP and Aβ on the cell surface and to a lesser extent in the cytoplasmic 
regions (Fig.15D-F). This is conducive to what was previously reported (Da Costa Dias et al., 
2013). Upon confirmation of transfection of SH-SY5Y cells with LRP::FLAG (Fig. 15H) 
there is a clear increase in total levels of LRP (Fig. 15G). This is concomitant with a decrease 
in Aβ levels, whereby levels are almost undetectable (Fig. 15I) in comparison to the non-
transfected cells (Fig.15B). See Fig. S2 (Appendix) for enlarged view of Fig. 15. 
In addition, an interesting finding upon transfection is the morphological transformation that 
occurs (Fig. 15G-K; 15G-K), whereby cells change from an elongated epithelial-like 
morphology to a less-differentiated morphology with enlarged nuclei. Since this was not a 
focus of this study, this was not further examined. However, these changes are being 
investigated in a separate study. 
 
Fig. 16. LRP::FLAG overexpression increases hTERT levels in SH-SY5Y cells. (A-L). 
Intracellular localisation and co-localisation of LRP (FITC-Green) and hTERT (APC-Red) as well as 
LRP::FLAG (FITC-Green) and hTERT in non- and LRP::FLAG transfected SH-SY5Y cells. (A) 
Endogenous LRP levels in SH-SY5Y cells, LRP localises to cytosol, nucleus and cell surface. (B) 
Endogenous hTERT levels in SH-SY5Y cells, hTERT is localised to the nucleus and the cytosol. 
(C&I) Nuclei are stained with DAPI (Blue). (G) LRP levels are increased in LRP::FLAG transfected 
cells. (H) LRP::FLAG expression is confirmed in transfected SH-SY5Y cells. There is co-localisation 
between hTERT and LRP and this increases in SH-SY5Y cells overexpressing LRP::FLAG. This is 
represented by yellow fluorescence in merged images (D&J), as white areas (E&K) and as 
fluorescence in the third quadrant of the 2D cytofluorograms (F&L). All images are at 630 X 
magnification and a resolution of 140 nm. Scale bars represent 10 µm. 
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As aforementioned, LRP expression in non-transfected SH-SY5Y cells occurs widely 
throughout the cells (Fig. 16A). In these cells, hTERT localises to the nuclear and cytosolic 
regions (Fig. 16B). Here, co-localisation occurs between LRP and hTERT, as represented by 
yellow fluorescence (Fig. 16D-F). white areas. These results confirm previously reported 
results (Naidoo et al., 2015; Otgaar et al., 2017). However, upon transfection of the SH-
SY5Y cells with LRP::FLAG (Fig. 16G), there is a clear increase in hTERT levels and 
intracellular localisation, as observed in Fig. 16H, which is furthermore shown by the 
increase in fluorescence intensity indicated in Fig. 15L. See Fig. S3 (Appendix) for enlarged 
view of Fig. 16. 
 
Fig. 17. Immunofluorescence microscopy in SH-SY5Y cells indicates co-localisation of 
hTERT and Aβ. (A-F) hTERT [APC-Red] (A) and Aβ [FITC-Green] (B) co-localise on the cell 
surface and intracellularly in SH-SY5Y cells. Nuclei are stained with DAPI [Blue] (C). Co-
localisation is represented by yellow fluorescence in the merged image (D), as white areas (E) and as 
fluorescence in the third quadrant of the 2D cytofluorograms (F). All images are at 630 X 
magnification and a resolution of 140 nm. 
Since we know of an antagonistic relationship between telomerase and Aβ in AD, as 
previously reported (Wang et al., 2015), confocal microscopy with the addition of 
Airyscan™ was employed to determine whether these two proteins co-localise in the cell. 
Here we observe that hTERT and Aβ do indeed co-localise within the cell as indicated by 
white areas in Fig. 17E and as detectable fluorescence in quadrant 3 of Fig. 17F. This 
furthermore suggests an interaction between the two proteins. Furthermore, this co-
localization is indicative of a possible association between these proteins. 
Co-localisation is presented as spatial overlap, indicated as yellow fluorescence in merged 
images (Fig. 15D, K; Fig. 16D, J; Fig. 17D). This is further presented by white areas, 
whereby, exact points of co-existence of the two relative proteins are seen (Fig. 15E; Fig. 
16E, K; Fig. 17E). In addition, 2D cytofluorograms indicate fluorescence of both proteins 
being detected, whereby, FITC (Green) is shown in the 1st quadrant, APC (Red) is shown in 
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the 2nd quadrant and overlap between these fluorophores is seen in the 3rd quadrant (Fig. 15F, 
L; Fig. 16F, L; Fig. 17F). See Fig. S4 (Appendix) for enlarged view of Fig. 17. 
4.2.4. LRP::FLAG overexpression significantly decreases intracellular Aβ42 levels in 
HEK293 cells 
Since immunofluorescence microscopy indicated that SH-SY5Y cells transfected with 
LRP::FLAG exhibited lower Aβ42 levels (Fig.13I), an Aβ42-ELISA was performed on both 
the HEK293 and SH-SY5Y cells to further quantify this reduction. 
 
Fig. 18. LRP::FLAG overexpression decreases intracellular Aβ42 levels in HEK293 cells.  
A significant decrease in total intracellular Aβ42 levels is observed in LRP::FLAG transfected cells. 
Aβ42 concentration is expressed as a % pg Aβ42 per mg total protein. Non-transfected HEK293 were 
set to 100 %. Error bars represent standard deviation, n=3 biological repeats. *p, 0.05, **p, 0.01, 
***p, 0.001; Student’s t-test. 
Upon analysis of intracellular Aβ42 levels in the non-transfected and transfected HEK293 
cells, it was observed that LRP::FLAG overexpression reduced these levels (Fig. 18).  A 
significant reduction of 53.7 % in intracellular Aβ42 was observed in the LRP::FLAG 
transfected HEK293 cells, when compared to non-transfected HEK293 cells (p= 0.0009). 
Aβ42 levels were not detectable in non-transfected SH-SY5Y and LRP::FLAG transfected 
SH-SY5Y cells on analysis with the ELISA assay (Data not shown). 
 
 
 
50 
 
4.2.5. Overexpression of LRP::FLAG significantly increases telomerase activity in HEK293 
and SH-SY5Y cells 
Multiple studies have reported that an increase in TERT expression results in an increase in 
telomerase activity (Bodnar et al., 1998; Counter et al., 1998). Thus, subsequently to 
determining that LRP::FLAG overexpression increases hTERT levels (Fig. 16G), relative 
telomerase activity was quantified via qPCR. In addition, since Aβ42 is known to be 
antagonistic with hTERT (Wang et al., 2015), telomerase activity was assayed in both the 
presence and absence of cytotoxic levels of Aβ42 (Da Costa Dias et al., 2014) to determine 
whether the abovementioned factors influenced telomerase activity in both HEK293 and SH-
SY5Y cells. 
 
Fig. 19: LRP::FLAG overexpression significantly increases telomerase activity in 
HEK293 cells. Relative telomerase activity (RU= relative units) is increased in HEK293 and 
HEK293 cells transfected with LRP::FLAG after treatment with cytotoxic levels of synthetic Aβ42 
(500 nM). All values were normalised against the negative controls; all negative control values were 
subtracted from the signal of each sample. This data is representative of the mean value obtained 
across all biological repeats for each cell line and each treatment. Error bars represent standard 
deviation, n=3 biological repeats. *p, 0.05, **p, 0.01, ***p, 0.001; Student’s t-test. 
Upon relative quantification of telomerase activity in both untreated and Aβ42 treated 
HEK293 and HEK293 transfected cells (Fig. 19), it was shown that indeed, LRP::FLAG 
overexpression increased telomerase activity. Furthermore, in the absence of Aβ42 (0 nM), 
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HEK293 transfected cells had approximately 2-fold higher telomerase activity (p=0.0067) 
when compared to non-transfected HEK293 cells. This is conducive to what was previously 
reported (Otgaar et al., 2017). When these cells were treated with cytotoxic levels of 
synthetic Aβ42, a significant decrease in the relative telomerase activity of both the non-
transfected (p= 0.0056) and LRP::FLAG transfected (p= 1.81452E-06) HEK293 cells was 
observed. Interestingly, in the presence of cytotoxic levels of Aβ42 (500 nM), HEK293 
transfected cells exhibited significantly higher telomerase activity (p=0.03) in comparison to 
non-transfected HEK293 cells treated under the same conditions. 
 
Fig. 20: LRP::FLAG overexpression significantly increases telomerase activity in SH-
SY5Y cells. Relative telomerase activity (RU= relative units) is increased in SH-SY5Y and SH-
SY5Y cells transfected with LRP::FLAG after treatment with cytotoxic levels of synthetic Aβ42 (500 
nM). All values were normalised against the negative controls; all negative control values were 
subtracted from the signal of each sample. This data is representative of the mean value obtained 
across all biological repeats for each cell line and each treatment. Error bars represent standard 
deviation, n=3 biological repeats. *p, 0.05, **p, 0.01, ***p, 0.001; Student’s t-test. 
Subsequent quantification of relative telomerase activity in the SH-SY5Y and SH-SY5Y 
transfected cells (Fig. 20) further indicated that LRP::FLAG overexpression results in an 
increase in telomerase activity. Upon assessment in non-transfected SH-SY5Y cells, very low 
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endogenous telomerase activity was observed. Moreover, upon treatment of these cells with 
cytotoxic Aβ42 levels, telomerase activity became almost negligible, with values similar to 
those of the negative controls. Additionally, in the absence of Aβ42, there was a significant 
increase in the relative telomerase activity in the SH-SY5Y cells overexpressing 
LRP::FLAG.This was in comparison to the non-transfected SH-SY5Ycells (p=0.00248) 
under the same conditions. Remarkably, when treated with 500 nM Aβ42, telomerase activity 
was significantly higher in the SH-SY5Y transfected cells when compared to the treated, non-
transfected SH-SY5Y cells (p= 8.62407E-05). 
4.2.6. Overexpression of LRP::FLAG rescues HEK293 and SH-SY5Y cells from Aβ42 – 
mediated cytotoxicity  
LRP/LR is a known receptor for Aβ42, whereby it is involved in the internalisation and 
therefore, the accumulation of Aβ42 intracellularly, thereby inhibiting cell proliferation and 
inducing apoptosis (Da Costa Dias et al., 2014). In addition, treatment of cells with 500 nM 
synthetic Aβ42 peptides has proven to mimic Aβ42 – mediated cytotoxicity (Da Costa Dias et 
al., 2014). Since it was revealed that LRP::FLAG overexpression increased LRP and hTERT 
levels with a concomitant decrease in Aβ42 levels, an MTT assay was performed to determine 
whether there was an effect on the viability of the transfected HEK293 and SH-SY5Y cells in 
the presence of cytotoxic levels of synthetic Aβ42 peptides. 
 
Fig. 21: LRP::FLAG overexpression rescues HEK293 cells from Aβ42 induced 
cytotoxicity. Cellular viability of HEK293 and HEK293 transfected cells, as determined by 3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT) assay post exogenous treatment with 
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500 mM synthetic Aβ42. Cell viability was assessed 48 h post-treatment and the untreated set to 100 
%.  Protocatechuic acid (PCA) was used as a positive control. Error bars represent standard deviation. 
n=3 biological repeats *p, 0.05, **p, 0.01, ***p, 0.001; Student’s t-test. 
Analysis of cellular viability in HEK293 cells (Fig. 21) showed treatment with cytotoxic 
levels of Aβ42 (to mimic Aβ42-induced cytotoxicity) reduced cellular viability significantly in 
non-transfected HEK293 cells, with a decrease of 32.68% seen in comparison to untreated, 
non-transfected HEK293 cells (set to 100% cell viability) (p=00976) (Fig. 21). HEK293 cells 
treated with 8 mM of the apoptotic inducer, PCA, were used as a positive control and 
displayed 6.36% cell viability.  
Interestingly, investigation of cell viability in HEK293 LRP::FLAG transfected cells (Fig. 
21), 48 h post-treatment with 500 nM synthetic Aβ42, revealed these cells exhibited a 
significant 62.62 % higher cell viability (p= 0.00105) when compared to non-transfected cells 
treated under the same conditions. Therefore, transfection with LRP::FLAG rescues HEK293 
cells from Aβ42- induced cytotoxicity. 
 
Fig. 22: LRP::FLAG overexpression rescues SH-SY5Y cells from Aβ42 induced 
cytotoxicity. Cellular viability of SH-SY5Y and SH-SY5Y cells transfected with LRP::FLAG as 
determined by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT) assay post 
exogenous treatment with synthetic Aβ42. Cell viability was assessed 48 h post-treatment and the 
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untreated set to 100 %.  PCA was used as a positive control. Error bars represent standard deviation. 
n=3 biological repeats. *p, 0.05, **p, 0.01, ***p, 0.001; Student’s t-test. 
Examination of cell viability in SH-SY5Y cells (Fig. 22) revealed that upon a 48-h treatment 
with 500 nM Aβ42 synthetic peptides, there was a marked decrease of 63.33 % (p=1.31433E-
07) in cell viability of the non-transfected SH-SY5Y cells. Whereby only 36.67 % of cells 
remained viable (untreated set to 100 %). However, when SH-SY5Y transfected cells were 
treated under the same conditions, they exhibited a significant 91.44 % higher viability in 
comparison to the treated, non-transfected cells. Non-transfected SH-SY5Y and LRP::FLAG 
transfected SH-SY5Y cells treated with 8 mM of the positive control, PCA, exhibited cellular 
viability of 6.76 % and 13.45 % respectively. 
Taken together, these data indicate the novel finding that LRP::FLAG overexpression rescues 
both HEK293 and SH-SY5Y cells from Aβ42-induced cytotoxicity. 
5. Discussion 
5.1. Alzheimer’s disease transgenic mouse study: 
Here, we establish the novel finding that treatment of 5XFAD transgenic mice through 
intranasal administration of the anti-LRP/LR specific antibody, IgG1-iS18, results in 
improved learning and short-term memory, decreased Aβ plaque formation and accumulation 
with a concomitant increase in mTERT levels. in vitro studies have shown that blockade of 
LRP/LR with IgG1-iS18 reduces Aβ shedding, decreases Aβ42 internalization and increases 
cell survival in the presence of Aβ (Jovanovic et al., 2013; Da Costa Dias et al., 2013; 
Jovanovic et al., 2014). Thus, we hypothesized that administration of IgG1-iS18 through the 
nasal mucosa, might lead to reduction in Aβ generation and toxicity and therefore, mitigate 
symptoms associated with AD, including reduced cognitive function and Aβ plaque 
formation. 
5.1.1. Intranasal administration of IgG1-iS18 decreases AD histopathological hallmarks and 
Aβ levels in brains of AD transgenic mice 
In testing this hypothesis, Dr. Ferreira- van der Merwe reported that administration of IgG1-
iS18 intranasally and biweekly for 8 weeks, significantly improved recognition and short-
term memory (Fig S1). The novel object recognition test showed mice treated with the anti-
LRP/LR specific antibody, IgG1-iS18, preferentially explored a novel object rather than a 
familiar object, therefore indicating an improvement in recognition memory. Furthermore, a 
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puzzle box test revealed that when mice were exposed to problem-solving tasks, IgG1-iS18 
treated mice took significantly less time to reach the relevant goal zone, compared to the 
control. Therefore, indicating a significant improvement in short term and learning memory. 
The results from the novel object recognition and puzzle box tests were hereby reported in 
summary for contextual purposes as these tests were performed by Dr. Ferreira-van der 
Merwe. These data are extensively analysed and discussed in Ferreira, Bignoux, Otgaar, et al. 
Oncotarget, in press. 
Since the memory tests provided positive results in the IgG1-iS18 treated mice, we decided to 
investigate whether this improvement in memory and cognitive function was due to an 
improvement in AD brain pathology. Therefore, histological analysis was performed to 
assess the effect on the β-amyloid load and its subsequent effects on tissue atrophy of the 
hippocampus of the AD mice. We observed a considerable decrease in vacuolization as well 
as Aβ plaque formation, key factors involved in causing neuronal loss and thus the 
behavioural and cognitive dysfunction experienced by AD sufferers (Serrano-Pozo et al., 
2011; Xiao et al., 2015). Furthermore, upon quantification, the amyloid load was 
significantly lower in the hippocampus of the IgG1-iS18 treated mice when compared to that 
of the PBS treated mice (Fig 5). It has been established previously, that hippocampal lesions 
result in moderate memory impairment (Broadbent et al., 2010) and altered executive 
functions in the puzzle box test (Nada et al., 2011). Therefore, we suggest that there is a 
direct correlation between the enhancement in memory and cognitive function and the 
amelioration of the AD brain pathology. 
To further substantiate the effect of nasal IgG1-iS18 treatment on Aβ levels, an Aβ42 ELISA 
and dot-blot analysis were performed. This was to assess the Tris-soluble (soluble) and 
GuHCl-soluble (insoluble) Aβ42 peptide levels, respectively, in the mouse hemi-brain 
homogenates from both treatment groups. Here, we demonstrated a significant decrease in 
both the soluble and insoluble Aβ42, expressly in the IgG1-iS18 treatment group (Fig. 6). This 
coincides with our previously published findings, whereby, IgG1-iS18 treatment of HEK293 
and SH-SY5Y cells lead to a decrease in Aβ levels (Jovanovic et al., 2013). Thus, we 
propose that the observations seen upon assessment of cognitive ability and brain pathology 
in the mice treated with the IgG1-iS18 antibody are causally related to the significantly lower 
Aβ42 levels revealed explicitly in these mice.  
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5.1.2. IgG1-iS18 treatment significantly increases APP brain levels.  
It has previously been reported that FRET analysis (Jovanovic et al., 2014) revealed a direct 
interaction between LRP/LR and γ-secretase and an indirect interaction between LRP/LR and 
β-secretase. Thereby, indicating that LRP/LR is involved in the APP cleavage process. 
Moreover, IgG1-iS18 blockade of LRP/LR impedes these interactions (Jovanovic et al., 
2015). Thereby, preventing the formation and shedding of Aβ1-42 by inhibiting the sequential 
cleavage of APP by the β- and γ-secretases (Jovanovic et al., 2013) without affecting the 
levels of these AD related proteins. Considering these formerly attained in vitro results, we 
wanted to confirm whether the IgG1-iS18 antibody treatment had no effect on the levels of 
LRP/LR, β- and γ-secretase as well as APP in the mouse brain tissue of these mice when 
compared to the PBS treated control mice. Western blot analysis indeed showed uniform 
levels of LRP/LR, β- and γ-secretase expression among the mice (Fig. 7). Therefore, this is 
suggestive that treatment with IgG1-iS18 does not modulate the gene-expression of these AD 
related proteins. Interestingly, in contrast to what was previously ascertained in vitro, we 
observed that treatment with the anti-LRP/LR antibody resulted in a significant increase of 
85.86 % in APP levels in these mice (Fig. 8).  Therefore, we suggest that this increase in APP 
levels is caused by the inhibition of the APP cleavage process, due to the diminished 
interaction between LRP/LR, β- and γ-secretase (Jovanovic et al. 2015). Furthermore, this 
occurs concomitantly with the observed reduction in Aβ1-42 production (Fig. 6). 
5.1.3. Intranasal IgG1-iS18 treatment significantly increases mTERT levels and 
phosphorylation of H2AX 
In addition to the abovementioned interactions between LRP/LR, β- and γ-secretase 
(Jovanovic et al., 2014), it was recently elucidated that LRP/LR co-localizes with the reverse 
transcriptase ribonucleoprotein, TERT, in both tumorigenic and non-tumorigenic cells 
(Naidoo et al., 2015; Otgaar et al., 2017). Furthermore, the interaction between these proteins 
was confirmed by co-immunoprecipitation assays (Naidoo et al., 2015). In addition to the 
role of TERT as the reverse transcriptase ribonucleoprotein in telomerase, TERT further 
performs non-telomeric functions. It has been reported that TERT plays a protective function 
against neuronal apoptosis caused by various stresses (Li et al., 2013) and furthermore, is 
involved in DNA damage responses and repair (Saretzki et al., 2014). It is recognized that the 
occurrence of and predisposition to AD, increases with age. This is supported by evidence 
showing that AD sufferers present shorter telomere lengths in their neuronal cells (Wang et 
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al., 2015), a key factor in cellular senescence and the aging process (Shay & Wright, 2005). 
Moreover, it has recently been reported that the pathological mechanisms of AD are related 
to human telomerase. Wang et al., 2015 illustrated in an in vitro setting, that Aβ1-40 and Aβ1-
42 inhibit telomerase activity by means of binding to telomeric DNA/RNA complexes of 
telomerase. Furthermore, Zhu et al., 2000 had previously established a neuroprotective 
function of TERT in an in vitro AD experimental model. Whereby, they reported an increase 
in vulnerability to Aβ-induced apoptosis upon downregulation of TERT and inhibition of 
telomerase activity in embryonic hippocampal neurons. Moreover, when they overexpressed 
TERT in this in vitro AD experimental model, they reported an increase in antiapoptotic 
responses. Altogether indicating that telomerase has a function in promoting cell survival 
(Zhu et al., 2000). Thus, we performed western blotting to establish if the observed 
improvement in cognitive ability and decrease in Aβ levels and plaque formation seen after 
antibody treatment, was accompanied by a simultaneous increase in mTERT levels. 
Interestingly, we revealed a significant increase in mTERT protein levels in the hemi-brain 
homogenates of the IgG1-iS18 treated mice when compared to the levels in the brain tissue of 
the PBS treated control (Fig. 9). Therefore, we propose that the observed decrease in Aβ 
levels, after treatment with IgG1-iS18, resulted in a reduction in neurotoxicity and hence a 
concomitant increase in mTERT levels. It is also possible that this increase in mTERT levels 
played an independent and additional neuroprotective role against the Aβ-induced 
neurotoxicity. This is suggested as TERT is known to have a protective role in the 
mitochondria, whereby TERT translocates to the mitochondria in the presence of ROS and 
aids in the protection of the organelle against mtDNA damage and apoptosis (Cong & Shay, 
2008). This is further suggested, as it is known that Aβ neurotoxicity is related to Aβ-induced 
neuronal apoptosis, which is primarily responsible for mitochondrial dysfunction (Mattson, 
1997) and DNA damage (Zhang et al., 1995; Deng et al., 1999), which are prevalent in AD 
sufferers.   
Since we observed an increase in mTERT levels and reports have shown that increases in 
TERT expression result in an increase in telomerase activity (Bodnar et al., 1998; Counter et 
al., 1998), we wanted to determine whether treatment with IgG1-iS18 influenced telomerase 
activity in the mouse brain tissue. We detected very low levels of telomerase activity with no 
significant change between control and treated mice (Fig 9) and therefore suggest that the 
increased levels in TERT expression observed in the mouse brain, have a neuroprotective 
function against age-related and Aβ-induced neurodegeneration rather than playing a role in 
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telomerase activity. Furthermore, studies have reported that adult mouse brains lack 
telomerase activity (Klapper et al., 2001) 
As aforementioned, Aβ neurotoxicity is associated with Aβ induced neuronal apoptosis. This 
occurs via oxidative stress and disrupted cellular calcium homeostasis, both of which, 
contribute to the aforestated DNA damage (Zhang et al., 1995; Deng et al., 1999) and 
mitochondrial dysfunction (Mattson, 1997). There are numerous factors involved in the DNA 
repair process as well as in signalling the presence of damage, which have shown to 
accumulate after double-strand DNA breaks. One such important response to DNA damage is 
the phosphorylation of H2AX (γH2AX) (Paull et al., 2000). This facilitates the recruitment of 
a subset of damage response and repair proteins. Masutomi et al., 2005 revealed that the 
DNA damage response was impaired in cells lacking hTERT. Moreover, this was due to a 
reduction in the phosphorylation of H2AX, thus implicating hTERT as a crucial component 
of the DNA damage response pathway. Subsequent to observing a decrease in neurotoxicity 
and an increase in mTERT levels after treatment with IgG1-iS18, we decided to investigate 
the levels of γH2AX present in the brain tissue. Surprisingly, the antibody treatment 
significantly increased levels of γH2AX by 10 %, whilst total H2AX levels remained 
unchanged (Fig. 11). It is possible that the increase in the phosphorylation of H2AX was due 
to the concomitant increase in mTERT and might contribute to the repair and protection 
against neurodegeneration as observed in this study. 
Therefore, intranasal administration of IgG1-iS18 improved cognitive function, reduced 
amyloid plaque formation and Aβ42 levels with a concomitant increase in APP and mTERT 
levels, together with an increase in H2AX phosphorylation. Ultimately, IgG1-iS18 prevents 
the pathological progression of AD in AD transgenic mice. 
 
5.2. Alzheimer’s disease in vitro study: 
The second part of this study involved an investigation into the effect of overexpressing 
LRP::FLAG on LRP, TERT and Aβ protein levels, as well as the resultant effect on 
telomerase activity and cell viability in the HEK293 and SH-SY5Y AD cell culture models. 
Here, the respective protein levels were assessed by western blotting and confocal 
microscopy with the addition of Airyscan™. Thereafter, Aβ42 levels were assessed by 
ELISA, telomerase activity via qPCR and cell viability by MTT analysis. 
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5.2.1. LRP::FLAG overexpression increases LRP and hTERT levels and diminishes Aβ 
production. 
HEK293 and SH-SY5Y cells are routinely used for neurological studies for their expression 
of neuronal markers and ease of transfection (for review see Schlachetzki et al., 2013). It has 
previously been reported that inducing overexpression of LRP::FLAG via stable transfection, 
with the pCIneo-moLRP::FLAG construct, increased TERT levels, telomere length and 
telomerase activity in HEK293 cells (Otgaar et al., 2017). Since HEK293 cells express 
relatively high levels of endogenous TERT and have detectable telomerase activity, these 
cells were used as a positive control. Western blotting was performed to assess endogenous 
levels of LRP and hTERT in the SH-SY5Y cells and compared to the HEK293 control line 
(Fig. 13). Here, it was shown that LRP and hTERT levels are significantly lower in the SH-
SY5Y cells in comparison to the HEK293 cells. HEK293 cells are reported to express 
relatively high levels of hTERT (Saretzki, 2014). Whereas, the SH-SY5Y are a somatic cell 
line of neuronal origin (Kovalevich & Langford, 2013) and mature neurons are reported to 
have low levels of endogenous TERT (Fu et al., 2000). Therefore, the SH-SY5Y cells were 
used as the experimental cell line. Thus, the HEK293 and SH-SY5Y cells provide a suitable 
in vitro model for LRP::FLAG overexpression, in order to study aspects of AD in cells with 
high and low telomerase activity, respectively.  
Therefore, the SH-SY5Y and HEK293 cells were stably transfected with the pCIneo-
moLRP::FLAG construct to induce overexpression of the LRP::FLAG protein. Confocal 
microscopy with the addition of Airyscan™ was performed in the SH-SY5Y cells to 
investigate the resultant effect of LRP::FLAG overexpression on LRP and hTERT levels, as 
well as co-localisation between these proteins. It was previously reported that LRP/LR both 
co-localises and interacts with hTERT in HEK293 and MDA_MB231 cells (Naidoo et al., 
2015). Here, it is seen that LRP and hTERT do indeed co-localise in the SH-SY5Y cells (Fig. 
16D-F) and that co-localisation occurs in the nuclear and cytosolic regions. In addition, 
confocal microscopy with Airyscan™ further reveals an increase in LRP (Fig. 16G) and 
hTERT (Fig. 16H) levels. Additionally, analysis via western blotting revealed that 
LRP::FLAG overexpression significantly elevated LRP levels in both the HEK293 (Fig. 14A, 
C) and SH-SY5Y (Fig. 14B, D) cells, by 58% and 165% respectively.  Since an increase in 
hTERT levels was observed with confocal microscopy, western blotting with subsequent 
densitometric analysis will further be performed to provide a more accurate quantification of 
these levels. Since co-localisation studies between LRP/LR and hTERT and LRP/LR and 
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Aβ42, have been previously reported in HEK293 cells (Da Costa Dias et al., 2013; Otgaar et 
al., 2017) confocal microscopy was not performed in this cell line.  
LRP/LR is a receptor of Aβ42 (Da Costa Dias et al., 2013) and is known to be involved in 
Aβ42 shedding (Jovanovic et al., 2013) and internalisation (Jovanovic et al., 2014). Thus, it 
was investigated whether there was co-localisation between LRP and Aβ42 in the SH-SY5Y 
cells.  Indeed, it was observed that LRP and Aβ42 co-localise on the cell surface, as previously 
shown upon cell surface analysis in HEK293 cells (Da Costa Dias et al., 2013). Interestingly, 
co-localisation was also observed in the cytosol. This is conducive to reports indicating that 
Aβ42 incorporates into cell organelles (Verdier & Penke, 2004) as well as reports concluding 
LRP/LR localises in the cytoplasm, where it plays a role in translational processes (Jovanovic 
et al., 2015). However, upon transfection with LRP::FLAG, Aβ42 levels are diminished (Fig. 
15I). This was a promising observation, considering Aβ42 is the known aetiological agent of 
AD (Choi et al., 2014), due to its role in the formation of amyloid plaques 
Confocal microscopy with Airyscan™ indicated a decrease in Aβ42 levels (Fig. 15) in the 
LRP::FLAG transfected cells. Thus, an Aβ1-42- ELISA was performed to provide a more 
quantitative measure of intracellular Aβ42 levels. As anticipated, there was a significant 
decrease observed in intracellular Aβ42 levels in the HEK293 transfected cells, when 
compared to the non-transfected HEK293 cells (Fig. 18). However, on assessment in SH-
SY5Y cells, Aβ42 levels were undetectable with the use of the Aβ1-42- ELISA. We suggest this 
is as these cells were not fully differentiated to the more mature neuron-like phenotype and as 
such do not express all neuronal markers (Kovalevich &Langford, 2013). Since we saw an 
increase in LRP and hTERT protein levels, we propose this concomitant decrease in Aβ42 
levels seen in both the SH-SY5Y (Fig. 15) and the HEK293 (Fig. 18) cells is owed to the 
antagonistic relationship between telomerase and Aβ in AD (Wang et al., 2015). The 
observed decrease in intracellular Aβ42 levels could be indicative of a decrease in Aβ42 
internalisation. This will be further assessed by forming an Aβ42-ELISA in the transfected 
and non-transfected HEK293 and SH-SY5Y cells, which have been treated with cytotoxic 
levels (500 nM) Aβ42. 
Since it was previously observed that LRP co-localises with hTERT and with Aβ42, 
respectively, it was of interest to assess whether hTERT and Aβ42 co-localise. Indeed, 
confocal microscopy with Airyscan™ analysis revealed co-localisation between hTERT and 
Aβ42 occurs within SH-SY5Y cells in the cytoplasm (Fig. 17). Wang et al., 2015 proposed 
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that there is an antagonistic relationship between telomerase and Aβ42 within neurons since 
Aβ42 is involved in the inhibition of telomerase activity, through the binding of the telomeric 
DNA/RNA template of telomerase (Wang et al., 2015). This, together with the results 
observed in the previous study strongly suggests there might be a direct interaction between 
these proteins. However, FRET analysis will be performed to confirm this. Altogether, 
overexpression of LRP::FLAG increases in LRP (Fig. 15G, 14G; Fig. 14) and hTERT levels 
(Fig. 16H) with a concomitant decrease in Aβ42 levels (Fig. 15I; Fig. 20).   
5.2.2. LRP::FLAG overexpression elevates telomerase activity.  
It has been reported by multiple studies that an increase in hTERT expression causes an 
increase in telomerase activity and that TERT behaves as the limiting factor for telomerase 
activity (Bodnar et al., 1998; Counter et al., 1998). Therefore, as we observed an increase in 
hTERT levels in the pCIneo-moLRP::FLAG transfected cells, we wanted to determine 
whether there was a resultant increase in telomerase activity. Since we know telomerase 
activity and Aβ42 have an antagonistic relationship (Wang et al., 2015) and that 
overexpression of LRP::FLAG decreased Aβ42 levels (Fig. 16; Fig. 18), we, therefore wanted 
to further determine the resulting effect on telomerase activity in both the absence and 
presence of cytotoxic levels of Aβ42. Hence, qPCR quantification of relative telomerase 
activity was performed in the HEK293 and SH-SY5Y cells. Here, it was confirmed, that there 
was indeed a significant increase in telomerase activity in both HEK293 (Fig. 19) and SH-
SY5Y (Fig, 18) cells, after transfection with LRP::FLAG. Since there was an observable 
increase in hTERT levels after LRP::FLAG transfection, we expected to see an increase in 
telomerase activity, since this follows the trend as previously reported on in HEK293 cells 
(Otgaar et al., 2017). Additionally, non-transfected HEK293 cells exhibited higher basal 
levels of telomerase activity, when compared to the non-transfected SH-SY5Y cells. This is 
expected as HEK293 cells exhibited higher endogenous hTERT levels (Fig. 16). Although 
telomerase expression is a known hallmark of cancer, it has been shown that ectopic 
expression of telomerase is not associated with malignancy (Morales et al., 1999). 
In addition, treatment with cytotoxic levels of Aβ42, thereby mimicking Aβ42-mediated 
cytotoxicity, caused a consequential reduction in telomerase activity in both transfected and 
non-transfected HEK293 and SH-SY5Y cells. Since we know Aβ42 induces apoptosis (Zhu et 
al., 2000) and inhibits telomerase activity (Wang et al., 2015), it is proposed that this 
reduction in telomerase activity is observed as a combination of these two factors.  
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Remarkably, however, telomerase activity was significantly higher in both the HEK293 (Fig. 
19) and SH-SY5Y (Fig. 20) transfected cells when treated with synthetic Aβ42 peptides and 
compared to their non-transfected counterparts treated under the same conditions. Thus, this 
novel finding suggests overexpression of LRP::FLAG significantly increases telomerase 
activity, even in the presence of Aβ42. This observation is proposed to be attributable to the 
fact that the increase in hTERT levels and the resulting increase in telomerase activity after 
overexpression of LRP::FLAG, is occurring prior to the manifestation of Aβ42-mediated 
cytotoxicity. Therefore, the overexpression of hTERT can compensate for the adverse effects 
caused by the high levels of Aβ42. We suggest, that since telomerase activity is increased in 
the LRP::FLAG transfected cells, that there is likely an increase in telomere length, as 
previously reported (Otgaar et al., 2017). However, this will be assessed by qPCR. 
5.2.3. Overexpression of LRP::FLAG rescues HEK293 and SH-SY5Y cells from Aβ42-
mediated cytotoxicity 
LRP/LR has been shown to be a receptor for synthetic Aβ42 peptides (Da Costa Dias et al., 
2013) and is involved in the internalisation and subsequent accumulation of Aβ42 
intracellularly (Jovanovic et al., 2014). This results in Aβ42-mediated cytotoxicity (Da Costa 
Dias et al., 2013). Furthermore, when cells are treated with 500 nM synthetic Aβ42 peptides, 
thereby mimicking Aβ42-mediated cytotoxicity, cell viability is decreased without affecting 
cell proliferation (Da Costa Dias et al., 2013). As we observed a reduction in Aβ42 levels (Fig. 
15; Fig. 18) together with an increase in LRP (Fig. 14; Fig. 15) and hTERT protein levels 
(Fig. 16), as well as telomerase activity (Fig. 19-18), we wanted to determine whether there 
was a resultant increase in cell viability in the presence of exogenous Aβ42 peptides. Thus, an 
MTT assay was performed on both the transfected and non-transfected HEK293 and SH-
SY5Y cells, including a 48-h exogenous treatment with 500 nM synthetic Aβ42 peptides. 
Interestingly, less cell death was observed in both the HEK293 (Fig. 21) and the SH-SY5Y 
(Fig. 22) transfected cells, post exogenous treatment with cytotoxic levels of Aβ42 peptides, 
when compared to the respective non-transfected cells. Therefore, indicating that 
LRP::FLAG overexpression rescues cells from Aβ-mediated cytotoxicity. We observed an 
increase in hTERT levels and telomerase activity concomitantly with a decrease in 
intracellular Aβ42 levels and an increase in cell viability of LRP::FLAG expressing cells, in 
the presence of cytotoxic Aβ42 levels. It is suggested that the mechanism by which hTERT 
interrupts the apoptotic cascade is attributed to the role of hTERT in the addition of 
TTAGGG repeats. This is consistent with the ability of telomerase inhibitors to induce 
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apoptosis (Chin et al., 1999; Fu et al., 1999), as well as the ability of telomerase to increase 
cell viability, as presented in this study. Furthermore, as ascertained in this study, hTERT 
localizes to both the nuclear and cytosolic regions (Fig. 16). Fu et al., 2000 elucidated that 
TERT can prevent the activation of caspases, before mitochondrial dysfunction can occur. 
TERT is reported to interact with the tumour suppressor, p53, through an interaction with the 
TERT-binding protein, TEP-1 (Li et al., 1999a). The pathological agent of AD, Aβ, has a 
functional role in mitochondrial dysfunction by disrupting calcium homeostasis through the 
formation of ion-permissible channels in the cell membrane, as well as causing oxidative 
stress (Mattson, 1997). In addition, ROS-induced alterations in mitochondrial membrane 
potential have been shown to be caused by p53, thereby, promoting apoptosis (Li et al., 
1999b). It is reported that p53 is present at elevated levels in neurons affected by amyloid 
plaques (de la Monte et al., 1997), as well as in transgenic mice overexpressing the Aβ 
peptide (LaFerla et al., 1996). Therefore, it is likely that TERT is furthermore exerting a 
protective effect in the cytoplasm, against the aforementioned detrimental effects of Aβ, 
through the modulation of p53-dependent mechanisms. Thus, the data acquired in the present 
study are consistent with this possibility and as such, we suggest TERT is playing a 
protective function against apoptotic stresses caused by Aβ and is thereby, providing a 
neuroprotective function. However, to confirm these effects, Annexin V and caspase assays 
will be performed. 
5.2.4. Conclusion. 
The pathological process of AD has been attributed to the accumulation and aggregation of 
Aβ42 (Choi et al., 2014), which occurs due to the abnormal proteolytic processing of APP, via 
the amyloidogenic pathway (Caetano et al., 2011). Furthermore, it is known that this 
accumulation promotes neuronal apoptosis as it mediates oxidative stress, mitochondrial 
dysfunction, DNA damage and caspase activation (Mattson, 1997; Zhang et al, 1995; Deng et 
al, 1999; Loo et al., 1993). It is suggested that the mechanism by which Aβ causes these 
effects, is either through direct interaction with cell surface receptors (Da Costa Dias et al., 
2011) or by incorporating into lipid membranes and cell organelles (Verdier & Penke, 2004). 
LRP/LR is a known receptor of Aβ42 and is furthermore involved in the shedding and 
internalisation of this peptide (Da Costa Dias et al., 2013; Jovanovic et al., 2014). 
Telomerase, the reverse transcriptase ribonucleoprotein responsible for telomere elongation 
and maintenance (Greider & Blackburn, 1987; Kim et al., 1994) is involved in AD. More 
specifically, AD sufferers present with shorter telomeres (Franco et al., 2006), suggestive of a 
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decrease in telomerase activity. Furthermore, TERT, provides extra-telomeric functions 
principally for the conservation of cell viability (Saretzki, 2014) and proliferation (Choi et al., 
2008; Cong & Shay, 2008; Park et al., 2009). Moreover, it has been reported that TERT can 
protect neurons against Aβ-induced apoptosis (Zhu et al., 2000) through its role in protecting 
against mtDNA damage and DNA repair (Mattson, 1997; Zhang et al, 1995; Deng et al, 
1999).  
The first part of this study is an original report proposing that intranasal administration of the 
anti-LRP/LR antibody, IgG1-iS18, decreases levels of soluble and insoluble Aβ42 in the 
whole brain and impedes accumulation of amyloid plaques in the hippocampus. We suggest 
that the concomitant increase in mTERT levels and H2AX phosphorylation lead to a decrease 
in neurotoxicity and accordingly conveyed improvement of cognitive abilities, learning and 
short-term memory. Therefore, we endorse the anti-LRP/LR specific antibody, IgG1-iS18, as 
a novel and powerful potential therapeutic strategy for treatment of AD. This therefore, 
motivates the employment of clinical studies to further investigate the effect of IgG1-iS18 on 
patients suffering from AD. The second part of this study has shown that LRP::FLAG 
overexpression increases hTERT expression, concomitantly increases telomerase activity, 
and concurrently decreases intracellular Aβ42 levels in HEK293 and SH-SY5Y AD cell 
culture models. We therefore propose that LRP::FLAG overexpression is providing a 
neuroprotective role as indicated by the rescue from Aβ42 -induced cytotoxicity observed in 
this study. Thus, overexpression of LRP::FLAG intracellularly, is a potentially powerful 
therapeutic for the treatment of AD.  
Taken altogether, IgG1-iS18 blocks internalisation and shedding of Aβ42, subsequently 
increasing mTERT protein levels, whilst overexpressing LRP::FLAG intracellularly, 
increases hTERT levels and consequently decreases Aβ42 production. Both treatment 
strategies are therefore, allowing TERT to provide a neuroprotective role in an AD setting. 
Therefore, this prompts the implementation of an AD transgenic mice study. Whereby a 
combinatorial treatment can be employed, by which IgG1-iS18 is adopted to block the 
internalisation and shedding of Aβ42. Whilst overexpression of LRP::FLAG intracellularly is 
applied to reduce Aβ42 production simultaneously. If the transgenic mouse study provides 
positive results, the study can proceed to clinical trials, whereby the treatments can be 
administered as protein-based drugs. Ultimately, Targeting LRP/LR in an AD context has 
provided insight into the disease and simultaneously presented alternative therapeutic options 
for halting disease progression in those suffering from AD. 
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7. Appendix  
 
Table S1: List of primary and secondary antibodies used for western blot analysis. 
Target 
Protein 
Primary antibody Secondary antibody 
APP Rabbit anti-APP, 1:1000 
(abcam 2027) 
anti-rabbit IgG-HRP, 1:2500 
(Cell Signaling Technology® 
7074S) 
mTERT Rabbit anti-hTERT,1:6666 
(abcam 183105)  
anti-rabbit IgG-HRP, 1:2500 
(Cell Signaling Technology® 
7074S)  
hTERT  Rabbit anti-hTERT, 1:200 
(abcam 183105) 
anti-rabbit IgG-HRP, 1:2500 
(Cell Signaling Technology® 
7074S) 
γH2AX Rabbit anti-Phospho-γH2AFX 
(PSER139), 1:5000  
(Sigma SAB4300213) 
anti-rabbit IgG-HRP, 1:3333 
(Cell Signaling Technology® 
7074S) 
LRP/LR Human anti-LRP/LR IgG-iS18, 
1:1000  
(Affimed) 
anti-human IgG-HRP, 1:5000  
(abcam 6858) 
β-secretase Rabbit anti-BACE1, 1:1000 
(abcam 2077) 
anti-rabbit IgG-HRP, 1:2000 
(Cell Signaling Technology® 
7074S) 
γ-secretase Rabbit anti-PS1, 1:1000 
(abcam 76083) 
anti-rabbit IgG-HRP, 1:2500 
(Cell Signaling Technology® 
7074S) 
β-actin Murine anti-β-actin-peroxidase, 
1:3333  
(Sigma A3854) 
 
- 
LRP::FLAG Anti-FLAG® M2 –Cy3 
(Sigma A9594) 
Rabbit anti-FLAG® M2 
- 
anti-rabbit IgG-HRP, 1:2500 
(Cell Signaling Technology® 
7074S) 
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Table S2: List of primary and secondary antibodies used for confocal imaging. 
Target 
Protein 
Primary antibody Secondary antibody 
LRP/LR Human anti-LRP/LR IgG-iS18, 
1:200  
(Affimed) 
anti-human IgG-FITC 1:500 
(abcam 6854) 
LRP::FLAG Murine anti-FLAG® M2, 1:200 
(Sigma F3165) 
anti- mouse IgG-FITC, 1:500 
(abcam 6785)  
hTERT Murine anti-hTERT, 1:200 
(Santa Cruz Biotechnology 
37751) 
 
Rabbit anti-hTERT, 1:200 
(abcam 183105)  
anti-mouse IgG CF647 1:500  
(Sigma) 
 
anti-rabbit IgG- Surelight® 
Allophycocyanin 
(abcam 72567) 
Aβ Rabbit anti-beta-Amyloid (1-
42), 1:200 
(Cell Signaling Technology® 
D9A3A) 
anti-rabbit - FITC 1:500  
anti-rabbit IgG- Surelight® 
Allophycocyanin 
(abcam 72567) 
 
 
Reagents: 
Table S3: List of reagents for Radioimmunoprecipitation assay (RIPA) lysis buffer  
Reagent 1X 2X 
NaCl 150 mM 300 mM 
Triton X-100 1 % 2 % 
Sodium deoxycholate 0.5 % 1 % 
SDS 0.1 % 0.2 % 
Tris-HCl (pH 8.0) 50 mM 100 mM 
EDTA (pH 8.0) 5 mM 10 mM 
Made up to 100 ml and stored at 4 ⁰C. 
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Table S4: List of reagents for 12% SDS-PAGE gel 
Reagent 12 % Separating 5 % Stacking 
dH20 2.15 ml 1.83 ml 
40% Acrylamide 1.5 ml 313 µl 
Resolving gel buffer 1.25 ml - 
Stacking gel buffer - 313 µl 
10% SDS 50 µl 25 µl 
10% APS 50 µl 25 µl 
TEMED 2 µl 2.5 µl 
Total volume /gel 5 ml 2.5 ml 
 
Table S5: List of reagents for Electrophoresis tank Buffer (pH 8.3) 
Reagent 1X 10X 
Tris 3 g 30 g 
Glycine 14.4 g 144 g 
SDS 1 g 10 g 
Made up to 1L with dH20 and stored at 4 ⁰C. 
 
Table S6: List of reagents for Transfer Buffer 
Reagent 10X 
Tris 30 g 
Glycine 144 g 
Made up to 1L with dH20 and stored at 4 ⁰C. 
Reagent 1X 
10X Transfer Buffer 100 ml 
Methanol 200 ml (20 %) 
Cold dH20 700 ml 
Stored at 4 ⁰C. 
 
Table S7: List of reagents for Phosphate Buffered Saline (PBS) (pH 7.2/7.4) 
Reagent 10X 
NaCl 80 g 
KCl 2 g 
74 
 
Sodium dihydrogen phosphate 
dodecahydrate (NA2HPO4.12H20) 
14.4 g 
Monopotassium phosphate (KH2PO4) 2.4 g 
Made up to 1L with dH20 and stored at room temperature. 
 
Table S8: List of reagents for GuHCl (pH 8.0) 
Reagent Concentration 
Guanidine HCl 5M 
Tris 50mM 
 
 
 
Fig. S1. Memory and cognitive function tests performed to assess the effect of treatment 
with IgG1-iS18. A) The percentage time spent exploring familiar and novel objects during the novel 
object recognition test. Error bars represent standard deviation, n=10 per group, *p, 0.05, **p, 0.01, 
***p, 0.001; Student’s t-test. B) Performance of the AD transgenic mice in the puzzle box test. 
Latencies scored to reach the goal zone during the 9 trials of the test are shown. Error bars represent 
standard deviation, n=12 per group, *p, 0.05, **p, 0.01, ***p, 0.001; Student’s t-test. (Adopted from 
Ferreira, Bignoux, Otgaar, et al. Oncotarget, in press) 
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